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Abstract
Oral squamous cell carcinoma is commonly preceded by a range of cell and tissue alterations
termed dysplasia, which indicate an increased risk of malignant transformation. Dysplasia is
classified according to severity into mild, moderate, severe and carcinoma in situ. The early
diagnosis, treatment and/or surveillance of these premalignant lesions are important factors in
preventing progression to oral cancer. The current gold standard for screening and diagnosis of
oral cancer and premalignant lesions is through histopathological diagnosis, which is limited
by inter and intra observer and sampling errors. Although other methods are available for
screening, most are not sensitive enough or do not provide enough information. Hence, there
is a requirement for a sensitive, non-invasive method that can provide real time information.
Raman spectroscopy fulfils these criteria, as it can provide detailed information on the
biological content of a sample, through the unique vibrations of its constituent molecules. By
analysing mild, moderate, and severely dysplastic formalin fixed paraffin preserved archival
tissue samples; first within the same patient (intra-patient study), then between patients (interpatient study), it was found that Raman spectroscopy could classify mild, moderate and severe
dysplasia in the same patient with an accuracy of over 90% in epithelium and over 80% in
connective tissue. The findings of the inter-patient study were that the different degrees of
dysplasia could be identified with an accuracy of 60%, while oral squamous cell carcinoma
could be differentiated from dysplasia and benign lesions with an accuracy of 70% in
epithelium and 80% in connective tissue. Confounding factors of the Raman classification of
pathology, such as smoking and inflammation, were also evaluated. In addition, protocols for
the processing of the Raman spectra of the oral tissues, including the subtraction of the wax
and substrate were developed.
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"Everything that living things do can be understood in terms of the jiggling
and wiggling of atoms”

-Richard Feynman, The Feynman Lectures on Physics, 1963
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Chapter 1:
1.1

Introduction

Thesis Outline

This study addresses the potential of Raman spectroscopy for applications in the diagnosis of
dysplastic and malignant oral disease, based on tissue biopsies. Patients with benign oral
lesions, mild, moderate and severe dysplasia and oral squamous cell carcinoma (OSCC) were
consented during their check-ups at the Dysplasia Clinic of the Dublin Dental Hospital. The
archival formalin fixed paraffin preserved (FFPP) samples from the patients with benign
lesions, different levels of dysplasia and OSCC were collected from the Central Pathology
Laboratory, St James’ Hospital, Dublin where all the oral biopsies are stored. The FFPP tissue
sections were assessed with Raman spectroscopy.
The broad objectives of the thesis were to;
1) investigate the Raman profiles of an oral squamous cell carcinoma (OSCC) cell line at
different phases of the cell cycle and to correlate these with biomarker expression in
the different phases of the cell cycle
2) optimise the processing of the Raman spectra from the FFPP tissue sections; which
included removing the wax and glass background.
3) discriminate between different degrees of dysplasia from the FFPP biopsies of
individual patients with serial biopsies (intra-patient study).
4) discriminate between benign, different degrees of dysplasia and OSCC from the FFPP
tissues in a cohort of patients (inter-patient study).
5) evaluate the influence of patient factors and clinical features on the Raman spectra of
the FFPP tissues
Chapter 1 of the thesis is a general introduction to oral cancer, dysplasia and Raman
spectroscopy.

1

Chapter 2 of the thesis is a review paper on the optical diagnosis of oral cancers, published in
the journal, Head & Neck.
The subsequent chapters address the aims/objectives of the thesis, chapters 3, 4, 5, 6 and 7
addressing the objectives 1, 2, 3, 4 and 5, respectively.
Chapter 8 presents a summary of the work, its clinical relevance and future perspectives.

1.2
1.2.1

Oral Squamous cell carcinoma
Overview/epidemiology

Oral cancers are prevalent worldwide, having an estimated incidence of 300,400 new cases and
145,400 deaths in 20121. Incidence is highest in South Central Asia, Eastern Europe and some
regions of Oceania1. Oral squamous cell carcinoma (OSCC) is the predominant malignancy in
most cases. It is more common in males than females, having a ratio of 1.5:1, and more
common in older persons (aged 50 or over)2. Nevertheless, there are currently changes in the
trend, manifest as an increase in incidence in young persons, which may be due to HPV
infection as opposed to the traditional risk factors such as smoking and tobacco3. In Ireland,
oral and pharyngeal cancers make up 3% of all cancers in males and 1.5% in females4.
1.2.2

Carcinogenesis

OSCC arises in the squamous epithelium and, like all cancers, is a multi-step process in which
cells acquire mutations that allow them to evade immune surveillance and divide
uncontrollably. Hanahan and Weinberg5 described six biological capabilities that enable
tumour growth and metastasis which are; sustaining proliferative signalling, evading growth
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and
activating invasion and metastasis. There are three main phases in carcinogenesis; 1) Initiation,
in which one or more mutations arise in the cells either spontaneously or as a result of exposure
to carcinogens, which increases the susceptibility of the cells for malignant transformation. 2)
Promotion, which involves the clonal expansion of initiated cells, producing a larger population
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of cells at risk for malignant transformation. 3) Progression, in which successive changes in
the transformed cells give rise to increasingly malignant sub-populations6.
1.2.3

Causes/risk factors

1.2.3.1

Smoking

Smoking is implicated in the development of a number of cancers including; lung, oesophageal,
pharyngeal and oral cancer. It is responsible for 71% of oral cancers in developed countries
and 37% in developing countries1. Over 60 carcinogens have been identified in cigarette
smoke, including; benzene, vinyl chloride, tobacco specific nitrosamines and aromatic
hydrocarbons such as benzopyrene, which has been linked to damage to the tumour suppressor
gene P537,8 . Smoking, independent of other risk factors such as alcohol consumption, has been
associated with a likelihood ratio of 2.15 of developing oral cancer9. The risk increases with
increased consumption and is higher in females compared to male smokers10.
1.2.3.2

Alcohol

As with cigarette smoking, alcohol consumption has been linked to a number of cancers such
as; oral, pharyngeal, oesophageal, and breast cancer11. It is estimated to be responsible for 3.5%
of cancer deaths, although the mechanisms by which it causes cancer are poorly understood12.
It is thought that acetaldehyde, the main metabolite of ethanol, may have a genotoxic effect.
Moreover, alcohol is believed to act as a solvent for other carcinogens which would explain
the synergistic relationship between smoking and alcohol consumption in the development of
oral cancer11,13. The amount and duration of alcohol consumed has a direct effect on cancer
risk and, in the oral cavity, the most frequently affected areas were found to be those most in
contact with the alcohol, such as the tongue, oropharynx and larynx9,11.
1.2.3.3

Smokeless tobacco and betel quid

Smokeless tobacco is used in either chewing or snuff form and is sometimes combined with
other substances such as betel quid. Similar to smoked tobacco, the carcinogenicity of
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smokeless tobacco is attributed to tobacco specific nitrosamines, although their concentrations
are different to the smoked form14. Smokeless tobacco has been associated with a relative risk
of 2.6% of developing oral cancer15. Betel quid chewing is prevalent in Taiwan, India, Papua
New Guinea, South-Africa and other Southeast Asian countries. However, it is not commonly
consumed in Ireland. Betel quid is prepared from the betel plant leaves and can be consumed
with or without tobacco. The areca nut extract in betel quid has demonstrated mutagenicity and
genotoxicity in animal models with areca alkaloids believed to be the major contributors16,17 .
1.2.3.4

Human Papilloma Virus (HPV)

The human papilloma virus (HPV) is generally associated with warts, epithelial cysts and
benign neoplasias. However, two subtypes, 16 and 18, have been linked to cancer development.
23% of oral squamous cell carcinomas (OSCC) were found to be positive for HPV and, of
these, two thirds were positive for HPV-16 and a third was positive for HPV-1818. Remarkably,
the survival of HPV positive cancer patients was higher than their HPV negative counterparts19.
The carcinogenicity of HPV is due to the expression of E6 and E7; two viral oncoproteins
which deregulate the cell cycle by interfering with the functions of PRB and P53, leading to
cell immortalisation20.
1.2.4

Anatomic site

The anatomic site at which oral cancer develops has been found to relate to its aetiology, as
cigarette smoking was associated with cancers in the retromolar area and floor of the mouth,
while alcohol was most associated with floor of the mouth cancers. The buccal mucosa was
associated with the lowest relative risk in both alcohol and cigarette smokers21. On the other
hand, HPV was associated with cancers in the oropharynx and base of the tongue. Anatomic
site is also linked to prognosis, base of the tongue cancers having the lowest five year survival
(41.6%) and labial mucosa the highest (81.5%)22. This may be related to the fact that
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carcinogens tend to pool at the base of the tongue and, moreover, the area is not easily visible,
so the condition is usually advanced by the time it is diagnosed.
1.2.5

Staging

As with most cancers, oral cancer is staged according to the TNM staging system, which is an
anatomical classification whereby;
T: Extent (size) of primary tumour
N: Regional lymph node involvement (absence or presence and extent)
M: Distant metastasis (absence or presence)

Table 1-1 T staging based on the size of primary tumour23
Tx
T0
Tis
T1
T2
T3
T4a
T4b

Tumour could not be assessed
No evidence of primary tumour
Carcinoma in situ (CIS)
Tumour < 2cm
Tumour 2- 4 cm
Tumour > 4cm
Tumour has invaded local structures such as cortical bone, muscles of the
tongue or skin of the face
Tumour has invaded into pterygoid plates, skull base or internal carotid artery

Table 1-2 N staging based on regional lymph node involvement23
Nx
N0
N1
N2
N3

Lymph nodes cannot be assessed
Absence of regional metastasis
Involvement of a single ipsilateral lymph node, no more than 3cm.
Single ipsilateral lymph node more than 3cm in size, or multiple ipsilateral or
contralateral lymph nodes, none more than 6cm
Involvement of lymph node more than 6cm in diameter
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Table 1-3 M staging based on distant metastasis23
Mx
M0
M1

Distant metastasis cannot be assessed
No distant metastasis
Distant metastasis

The TNM classification is used to determine cancer stage, which is important in making
decisions in treatment choice and patient prognosis.
Table 1-4 TNM classification23
Stage
0
I
II
III

T stage
Tis
T1
T2
T3
T1/2/3
T4a
T1/2/3
T1/2/3

IV

N stage
N0
N0
N0
N0
N1
N0
N2/3
N1/2/3

M stage
M0
M0
M0
M0
M0
M0
M0
M1

Another important classification is the histological grade, whereby the carcinoma is divided
into 4 grades depending on the proportion of the tumour resembling the tissue of origin;
Table 1-5 Histological classification24
Grade I
Grade II
Grade III
Grade IV

1.2.6

Well differentiated (<25% undifferentiated cells)
Moderately differentiated (<50% undifferentiated cells)
Poorly differentiated (<75% undifferentiated cells)
Anaplastic or pleomorphic (>75% undifferentiated cells)

Oral Cancer Biomarkers

A number of biomarkers have been considered for the assessment of oral cancer risk,
progression, and survival. Epidermal growth factor receptor (EGFR) expression has been
studied in oral cancer, as EGF is involved in many cell signalling pathways such as
proliferation, apoptosis and angiogenesis25,26. EGFR has been associated with a higher risk
(1.18%) of oral cancer development27, higher tumour grade28, and poor survival29. P53, a
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tumour suppressor gene, is commonly expressed in a mutated form in oral cancers30,31. Its
expression increases according to the degree of dysplasia in premalignant lesions32. However,
no distinct association was found between P53 expression and oral cancer patient outcome or
survival33,34. Cyclin D1 is a protein required for the progression of the cell cycle from G1 to S
phase35. Overexpression of cyclin D1 has been linked to recurrence and reduced overall
survival in oral cancer patients36,37. Thus far, none of the aforementioned biomolecules has
been established in routine clinical tests for oral cancer. There may be a need for studies with
greater statistical power before it can be determined whether any of these biomolecules could
serve as biomarkers for oral cancer.
1.2.7

Diagnosis

Oral cancer can manifest as an endophitic (inward growth) or exophytic (outward growth) that
can be a white or red patch or an area of ulceration. Some are symptomless, while others may
be associated with bleeding, pain and/or soreness. In the more advanced stages, patients may
present with symptoms like difficulty swallowing and swollen/tender lymph nodes in the
neck38. Especially at the early stages, oral cancer may resemble other benign oral lesions.
Therefore, after eliminating the possibility of other benign conditions, a suspicious lesion is
biopsied by the dentist and sent for histopathological examination, which is the gold standard
for oral cancer diagnosis. Other diagnostic aids include toluidine blue staining and brush
biopsy, which are discussed in more detail in chapter 2. Early diagnosis is very important in
oral cancer as stage at diagnosis is the most important prognostic factor39. After the initial
diagnosis of OSCC is made, the stage of the tumour and presence of lymph node or distant
metastasis is determined by the use of imaging techniques such as MRI, CT, and chest X rays40.
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1.2.8

Management

Oral cancers are treated with surgery, radiation therapy and chemotherapy, either as single
modalities or in combination (multimodality). Several factors affect the choice of management
in oral cancer patients;
1. The extent of the disease; this depends on the TNM staging system as early small
tumours are more amenable to radiation or surgery as a single modality therapy, while
larger, more advanced tumours require more extensive surgical approaches and are
more likely to have lymph node involvement. These are usually treated with
multimodality therapy, in which surgery is coupled with pre or postoperative radiation
and/or chemotherapy40-42.
2. Patient factors; the age of the patient, compliance, and presence of comorbidities are all
factors in determining the course of treatment in oral cancer41.
Postoperative surveillance or follow up is crucial in oral cancer, as the tumour may recur or the
patient can develop second primary tumours, which are tumours that develop in a different site
in the oral cavity and are not metastasis from the primary tumour. Up to 30% of male and 20%
of female patients develop second primary tumours2. The recommended follow up is every 23 months in the first year, every 3-4 months in the second year, every 4 months in the third
year, and every 5 months in the fourth year. Thereafter, a yearly follow up is recommended40.

1.3
1.3.1

Potentially Malignant Oral Disorders and Dysplasia
Potentially Malignant Oral Lesions

Potentially malignant lesions are defined as; ‘a morphologically altered tissue in which cancer
is more likely to occur than its apparently normal counterpart’43. The most commonly occurring
potentially malignant lesion is leukoplakia, defined as; ‘a predominantly white lesion of the
oral mucosa that cannot be characterized as any other definable lesion’43. Leukoplakias are
further classified, according to clinical appearance, into homogenous and non-homogenous
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lesions. Homogenous lesions are usually flat and thin and have a reduced risk of malignant
transformation compared to non-homogenous lesions. Non homogenous lesions carry an
increased risk of malignant transformation and include; speckled, nodular and verrucous
leukoplakia. Erythroplakia is defined as ‘a fiery red patch that cannot be characterised clinically
or pathologically as any other definable lesion’43. Erythroplakia may be smooth or nodular and
has the highest potential for malignant transformation of any oral lesion43.
1.3.2

Oral dysplasia

While leukoplakia and erythroplakia are clinical terms which describe the appearance of the
lesions, dysplasia is a histological term which describes the cell morphology and tissue
architecture. Depending on the degree of cellular atypia and architectural changes, dysplasia is
classified into mild, moderate, severe and Carcinoma in situ CIN. Dysplasia indicates an
increased risk of malignant transformation and has been reported to occur in 5-25% of oral
leukoplakias, while almost all erythroplakias show some degree of dysplasia44,45.
1.3.3

Potentially Malignant Oral Conditions

Potentially malignant oral conditions are described as; ‘A generalized state associated with a
significantly increased risk of cancer’46. A number of these conditions exist, such as; PlummerVinson syndrome, oral submucous fibrosis, syphilis, xeroderma pigmentosum and discoid
lupus erythematosus (DLE), all of which are associated with epithelial atrophy46.
1.3.4

Progression

It is hard to predict which potentially malignant oral lesions will progress to OSCC, but some
factors have been associated with an increased risk, such as the presence of leukoplakia in nonsmokers and dysplastic changes47. However, histological grade is not necessarily an indicator;
severe dysplasia may not progress, while mild dysplasia can progress to OSCC 48. Intra-oral
site and size of the lesion were not found to be significant predictive factors either49. Molecular
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markers such as loss of hetrozigosity (LOH) on chromosomes 3p/9p, DNA content and P53
expression levels have, however, shown promise in predicting OSCC development49.
1.3.5

Diagnosis

The diagnosis of potentially malignant oral disorders is similar to that for OSCC, as it starts by
exclusion of other differential diagnosis, followed by a biopsy and histopathological
examination. The problem with this system is that it is subjective and prone to inter and intra
observer errors50. Additionally, a biopsy may not be representative of the whole lesion, and
studies looking at the histology of tumours post operatively and comparing them to the preoperative biopsies have found that, in a significant number of cases, a neoplasia or carcinoma
in-situ was misdiagnosed48.
1.3.6

Management

The current recommendation for management of oral premalignant lesions is that moderate and
severely dysplastic oral lesions are removed either by surgery, laser or cryotherapy, while
lesions with no or mild dysplasia are followed up every sixth month or third month
respectively. Nonetheless, removal of the lesion was not found to significantly reduce the risk
of OSCC development51.

1.4

Raman Spectroscopy

The current methods used in the diagnosis of oral premalignant and malignant lesions have
their limitations. The standard method which is a conventional oral exam and histopathology
is limited by intra and inter observer errors in addition to sampling errors48,50. Moreover
dysplasia or OSCC may develop in an area of normal looking mucosa. Adjuncts such as oral
brush biopsy and toluidine blue staining also have their limitations as they may produce false
negative results and there is no information as to whether they can predict the probability of
malignant transformation52. This demonstrates the need for new techniques for screening and
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diagnosis. Optical diagnostics techniques, such as reflectance imaging, fluorescence imaging,
and Raman spectroscopy are fast and non-invasive. They can have potential applications in the
diagnosis of dysplasia and cancer which is discussed in more detail in chapter 2.
1.4.1

Theory

When electro-magnetic (EM) radiation interacts with a sample, it may be absorbed, or
scattered. Most scattering is elastic, named Rayleigh scatter after the physicist who first
described it, whereby the emitted (scattered) photon has the same energy as the incident photon.
Mie scattering, named after the German physicist who first described it, is a similar process
which dominates when the scatterers are larger than the wavelength of the light53. In 1928, the
Indian physicist C.V Raman demonstrated experimentally that a small amount of the scattered
radiation, about 1 in 1x106, is of a different energy than the incident photon, and the
phenomenon came to be known as the Raman effect54. The Raman effect is the result of
coupling of the molecular vibrational states with the photon, via the induced polarisation. If the
sample molecules gain energy from the incident photon, the emitted photon has less energy
than the incident one, as a result of the generation of a vibrational quantum. This effect is called
Stokes Raman scattering. Conversely, if the molecule is in excited higher vibrational state it
may lose energy to the emitted photon and go back to the ground state and the emitted photon
would have more energy than the incident one. This effect is called anti- Stokes Raman
scattering. Whether or not a molecule is Raman active depends on the polarisability of a
sample, which determines the degree of scattering when exposed to EM radiation54. The Raman
scattered light can be collected by a spectrometer and displayed as a Raman spectrum, in which
the peaks (bands) correspond to Raman frequency shifts (measured in wavenumbers cm-1)
caused by the characteristic vibrations in the molecules of a sample.
The presence of an electric field E induces in the molecule an electric dipole µ given by;
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𝜇 = 𝛼𝐸
Equation 1-1

where α is the polarisability, If the electric field is oscillating, which is the case for photons,
the equation is given by;
𝜇 = 𝛼𝐸0 cos(2𝜋𝜈0 𝑡)
Equation 1-2

where E0 is the electric field strength of the incident field, and ν0 is the frequency. An oscillating
dipole will radiate electromagnetic energy at the frequency of oscillation. Polarisability is
related to the degree to which electrons in a molecule can be displaced relative to the nucleus
by the electromagnetic field of a photon. This displacement is described below.
𝑞 = 𝑞0 cos(2π𝜈𝑣𝑖𝑏 𝑡)
Equation 1-3

where q0 is the amplitude of nuclear displacement and νvib is the frequency of the vibrational
mode. If the nuclear displacement is small, then the polarisability can be approximated using
the following equations.
𝜕𝛼
𝛼 = 𝛼0 + ( ) 𝑞
𝜕𝛼
Equation 1-4

where α0 is the polarisability of a molecule in its equilibrium position and (∂α /∂q) is the rate of
change of α with respect to the change in q, evaluated at the equilibrium position. Combining
Equation 1-3 and Equation 1-4 produces.
𝜕𝛼
𝛼 = 𝛼0 + ( ) 𝑞0 𝑐𝑜𝑠(2𝜋𝜈𝑣𝑖𝑏 𝑡)
𝜕𝛼
Equation 1-5

Combining Equation 1-2 and Equation 1-5 results in.
𝜕𝛼
𝜇 = 𝛼0 𝐸0 cos(2𝜋𝜈0 𝑡) + ( ) 𝑞0 𝐸0 𝑐𝑜𝑠(2𝜋𝜈0 𝑡)𝑐𝑜𝑠(2𝜋𝜈𝑣𝑖𝑏 𝑡)
𝜕𝛼
Equation 1-6
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This equation can be rearranged to describe three processes.
𝜕𝛼 𝑞0 𝐸0
µ = 𝛼0 𝐸0 cos(2𝜋𝜈0 𝑡) + (
) {cos[(2𝜋(𝜈0 − 𝜈𝑣𝑖𝑏 )𝑡] + cos[2𝜋(𝜈0 + 𝜈𝑣𝑖𝑏 )𝑡]}
𝜕𝑞 2
Equation 1-7

The first term describes Rayleigh scattering, as the scattered photon has the same frequency as
the incident photon (ν0). The second term describes Stokes scatter, as the difference between
incident and scattered photon frequency is ν0-νvib, while the third term describes anti-Stokes
scatter, as the difference between incident and scattered photon is ν0+νvib. The Boltzman
distribution determines the relative intensities of Stokes and anti-Stokes scattering, which is
dependent on the number of molecules in an excited state compared to those in the ground
state. At room temperature, most of the molecules are in the ground state, and hence Stokes
scattering is much more prevalent than anti-Stokes scattering.
1.4.2

Instrumentation

The different components of a Raman microspectrometer are shown in schematic form in
Error! Reference source not found.. The source of the monochromatic incident light is a laser a
nd different laser wavelengths can be used, from ultra violet through visible to near infra-red,
the choice of wavelength depending on the application. The interference filter is a clean-up
filter which only allows the laser output through, while the neutral density filter determines the
laser intensity, which is adjustable. For biological samples, coupling the Raman spectrometer
to a microscope facilitates focusing on different regions of the cell or tissue. The objective lens
both delivers the incident laser light and collects the backscattered (emitted) light. The
holographic notch filter reflects the same wavelength as the incident light to remove all the
Rayleigh scattered light and everything outside this range is considered Raman scatter and is
transmitted. The grating is used to disperse the light and the groove density (measured in
grooves/mm) determines the spectral resolution, higher groove density corresponding to higher
resolution. Typically, gratings between 300 and 1800 grooves/mm are used. Other
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determinants of spectral resolution include the wavelength, longer wavelengths having a higher
spectral resolution, and the spectrometer length, which is the distance between the grating and
the detector, longer distances providing higher resolution. Charge coupled device (CCD)
detectors are commonly used with Raman spectroscopy as they are very sensitive to light. They
also allow multichannel operation, so the entire Raman spectrum can be detected in a single
acquisition.
Laser

Mirror
Interference
Filter

CCD Detector

Neutral
Notch Filter
Density
Grating

Filter

Objective
Sample Stage

Figure 1.1 A schematic of a Raman microspectrometer based on the Horiba Jobin Yvon
LabRAM HR 800*
* Raman spectrometer model used in this study.
1.4.3

Use in Diagnostics

There has been a lot of interest in the use of Raman spectroscopy in medical diagnostics since
its introduction to the field of diagnostics nearly 20 years ago55. Its qualities, such as minimal
sample preparation, speed, non-invasiveness, label free nature, and the fact that it gives both
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qualitative and quantitative information on the molecular content of a sample make it
particularly suited to such applications. Raman spectroscopy has shown promise in the field of
microbiology by not only identifying the bacterial signatures but also response to antibiotics56.
Furthermore, it has been studied for use in the diagnosis of coronary atherosclerosis and blood
components57,58. Surface-enhanced Raman scattering (SERS) has been studied for use in
detecting various biomolecules such as glucose, hemoglobins and RNAs59. It can also detect
low levels of viral pathogens60.
1.4.4

Use in Cancer Diagnosis

The majority of the research on the diagnostic applications of Raman spectroscopy has been
aimed at cancer diagnosis, either through in–vitro, ex-vivo (such as cytology, histology or the
use of biofluids) or in-vivo techniques. Raman spectroscopy was successfully used to
differentiate between normal and neoplastic lymphocytic cell lines mainly based on changes in
DNA and protein profiles61. Ex-vivo studies have been carried out on breast histological
samples and one study found that Raman Spectroscopy could discriminate between breast
cancer and normal/benign conditions with a sensitivity and specificity of 94% and 96%
respectively62. Similarly, Raman Spectroscopy has been used in cervical pathology to identify
cancerous and precancerous stages63. Biofluids have a number of advantages which make them
ideal for diagnostic tests as their collection is very simple, can be done repeatedly, and is noninvasive. SERS on serum samples was used to identify prostate specific antigen (PSA) with
diagnostic accuracy of up to 98%64,65. SERS on saliva samples could discriminate healthy from
OSCC with an accuracy of 73%.66 A number of studies have looked into the in-vivo
applications of Raman spectroscopy. Theoretically, Raman spectroscopy can be a very
powerful diagnostic aid and could be used on mucosal and epithelial surfaces such as oral,
cervical and skin by direct contact with the Raman probe and on the visceral surfaces by use
with a needle or an endoscopic instrument. A study used Raman spectroscopy in the diagnosis
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of skin cancers and discriminating different cancerous and benign lesions which yielded very
high sensitivity but lower specificity67. Another study used Raman spectroscopy during
gastrointestinal endoscopy by coupling the fiberoptic Raman probe with the endoscopic
instrument, and compared normal to diseased states68. A good application for in-vivo Raman
spectroscopy could be the examination of surgical margins during cancer surgery and one study
has found promising results with margin assessment in breast cancer surgery69. However, these
studies are hampered by small patient numbers which in turn reduces the ability of the
classifiers, which are based on machine learning algorithms. Nevertheless, they demonstrate
the possibility of Raman applications for in-vivo diagnostics.
1.4.5

Use in Oral Cancer

There has been a lot of interest in the use of Raman spectroscopy for the diagnosis of oral
cancers, especially as the oral cavity is very accessible which facilitates ex-vivo and in-vivo
Raman spectroscopic diagnosis. Inadequate resection margins in oral cancer surgery increase
the likelihood of local recurrence70. The use of Raman spectroscopy as an aid in delineation of
OSCC surgical margins has shown that OSCC can be discriminated from surrounding normal
structures with a high degree of accuracy though it’s more likely to misclassify with
surrounding normal and dysplastic epithelium71. Water concentration was found to be higher
in tumours compared to normal tissue72. An in-vivo study study by Malik et al found that
Raman spectroscopy can predict local recurrence in oral cancers with a sensitivity of 80% and
specificity of 30%73.
1.4.6

Use in Oral dysplasia and premalignant lesions

There have been relatively few studies looking at the use of Raman spectroscopy for dysplastic
oral lesions. One study that induced dysplasia in the palate of a rat model was able to distinguish
between normal mucosa and low and high grade dysplasia with accuracies of 85 and 100%
respectively74. Another study looking at surgical margins in sections of OSCC found that the
16

accuracy of the Raman classification for dysplastic tissue was only 48%71. Using OSCC and
dysplastic cell lines and comparing them to normal cells, a study has found that Raman
spectroscopy could discriminate between malignant, dysplastic and normal cells based on
varying nucleic acid, protein and lipid profiles75. Interestingly, in all of these studies, the
differences between malignant and normal were very noticeable, while the dysplastic changes
seem to fall somewhere in between. Similar results have been reported from tissue studies
which looked at normal, inflammatory or benign, premalignant and malignant oral lesions76-78.
Overall these studies suggest that Raman spectroscopy can discriminate between normal
mucosa and malignancy but in the case of oral dysplasia there have been no studies to show
the effect of the different degrees on the classification of Raman spectroscopy. The use of
Raman spectroscopy for oral premalignant and malignant lesion diagnosis is discussed in more
detail in chapter 2, which is a review of optical techniques in oral cancer diagnosis.

17

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics,
2012. Ca-a Cancer Journal for Clinicians 2015;65:87-108.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncology
2009;45:309-316.
3. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S,
Rosenberg PS, Bray F, Gillison ML. Worldwide Trends in Incidence Rates for Oral Cavity and
Oropharyngeal Cancers. Journal of Clinical Oncology 2013;31:4550-4559.
4. Registry NC. Cancer in Ireland 1994-2015 with estimates for 2015-2017: Annual Report of
the National Cancer Registry. Cork, Ireland: National Cancer Registry, 2017.
5. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144:646674.
6. Weston A, Harris CC. Multistage Carcinogenesis. In: DW KR, Pollock RR, Weichselbaum,
ed. Holland-Frei Cancer Medicine. Hamilton: BC Decker, 2003.
7. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke
carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene
2002;21:7435-7451.
8. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens
in tobacco and tobacco-smoke. Carcinogenesis 1988;9:875-884.
9. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chu C, Paula Curado M, Dal Maso L,
Dauct AW, Fabianova E, Wunsch-Filho V, Franceschi S, Hayes RB, Herrero R, Koifman S,
La Vecchia C, Lazarus P, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan
AF, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei
Q, Winn DM, Zaridze D, Zatonski W, Zhang Z-F, Berthiller J, Boffetta P. Alcohol drinking in
never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck
cancer: Pooled analysis in the international head and neck cancer epidemiology consortium.
Journal of the National Cancer Institute 2007;99:777-789.
10. Muscat JE, Richie JP, Thompson S, Wynder EL. Gender differences in smoking and risk
for oral cancer. Cancer Research 1996;56:5192-5197.
11. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncology 2006;7:149-156.
12. Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC, Miller P, Shield KD,
Ye Y, Naimi TS. Alcohol-Attributable Cancer Deaths and Years of Potential Life Lost in the
United States. American Journal of Public Health 2013;103:641-648.
13. Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, Curado MP, Dal
Maso L, Daudt AW, Fabianova E, Fernandez L, Wuensch-Filho V, Franceschi S, Hayes RB,
Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos
E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P,
18

Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM,
Shangina O, Pilarska A, Zhang Z-F, Ferro G, Berthiller J, Boffetta P. Interaction between
Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the
International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiology
Biomarkers & Prevention 2009;18:541-550.
14. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic
review. Thorax 2003;58:435-443.
15. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet
Oncology 2008;9:667-675.
16. Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical
carcinogenesis: current awareness and future perspectives. Oral Oncology 2001;37:477-492.
17. Bhide SV, Shivapurkar NM, Gothoskar SV, Ranadive KJ. Carcinogenicity of betel quid
ingredients: feeding mice with aqueous extract and the polyphenol fraction of betel nut. British
Journal of Cancer 1979;40:922-926.
18. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head
and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiology
Biomarkers & Prevention 2005;14:467-475.
19. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH,
Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML.
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England
Journal of Medicine 2010;363:24-35.
20. zurHausen H. Papillomavirus infections - A major cause of human cancers. Biochimica Et
Biophysica Acta-Reviews on Cancer 1996;1288:F55-F78.
21. Jovanovic A, Schulten E, Kostense PJ, Snow GB, Vanderwaal I. Tobacco and alcohol
related to the anatomical site of oral squamous cell carcinoma. Journal of Oral Pathology &
Medicine 1993;22:459-462.
22. Zini A, Czerninski R, Sgan-Cohen HD. Oral cancer over four decades: epidemiology,
trends, histology, and survival by anatomical sites. Journal of Oral Pathology & Medicine
2010;39:299-305.
23. (AJCC) AJCoC. AJCC Cancer Staging Manual. Chicago, Illinois.: Springer-Verlag, 2002.
24. Roland NJ, Caslin AW, Nash J, Stell PM. Value of grading squamous cell carcinoma of
the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and
Neck 1992;14:224-229.
25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225
modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the
head and neck. Cancer Research 1999;59:1935-1940.
26. Ciardiello F, Caputo R, Bianco R, Damiano V, Fentanini G, Cuccato S, De Placido S,
Bianco AR, Tortora G. Inhibition of growth factor production and angiogenesis in human
19

cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase
inhibitor. Clinical Cancer Research 2001;7:1459-1465.
27. Benchekroun MT, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren
H, Lang W, Fan Y-H, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR,
Mao L. Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of
Oral Cancer. Cancer Prevention Research 2010;3:800-809.
28. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, Barbieri V, Jank S, Doppler
W, Rasse M, Norer B. High EGFR expression predicts poor prognosis in patients with
squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based
immunohistochemical analysis. Oral Oncology 2007;43:193-198.
29. Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R. Expression of
EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncology 2004;40:532537.
30. Langdon JD, Partridge M. Expression of the tumour suppressor gene p53 in oral cancer.
British Journal of Oral & Maxillofacial Surgery 1992;30:214-220.
31. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain
mutated p53 tumor-suppressor genes. Oncogene 1992;7:927-933.
32. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN. Activation of
p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer
Research 1994;54:321-326.
33. Li L, Fukumoto M, Liu D. Prognostic significance of p53 immunoexpression in the survival
of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy.
Oncology Letters 2013;6:1611-1615.
34. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous
cell carcinomas of the head and neck. Journal of Oral Pathology & Medicine 2000;29:413425.
35. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein
required for cell cycle progression in G1. Genes & Development 1993;7:812-821.
36. Michalides R, Vanveelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of
cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell
carcinomas of the head and neck. Cancer Research 1995;55:975-978.
37. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes
CJ, Sutherland RL. Cyclin D1 and p16(INK4A) expression predict reduced survival in
carcinoma of the anterior tongue. Clinical Cancer Research 1999;5:2810-2819.
38. Varela-Centelles P, Lopez-Cedrun JL, Fernandez-Sanroman J, Seoane-Romero JM, de
Melo NS, Alvarez-Novoa P, Gomez I, Seoane J. Key points and time intervals for early
diagnosis in symptomatic oral cancer: a systematic review. International Journal of Oral and
Maxillofacial Surgery 2017;46:1-10.

20

39. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squamous cell carcinoma: Review
of prognostic and predictive factors. Oral Surgery Oral Medicine Oral Pathology Oral
Radiology and Endodontics 2006;102:67-76.
40. Genden EM, Ferlito A, Silver CE, Takes RP, Suarez C, Owen RP, Haigentz M, Jr., Stoeckli
SJ, Shaha AR, Rapidis AD, Pablo Rodrigo J, Rinaldo A. Contemporary management of cancer
of the oral cavity. European Archives of Oto-Rhino-Laryngology 2010;267:1001-1017.
41. Shah JP, Gil Z. Current concepts in management of oral cancer - Surgery. Oral Oncology
2009;45:394-401.
42. Luryi AL, Chen MM, Mehra S, Roman SA, Sosa JA, Judson BL. Treatment Factors
Associated With Survival in Early-Stage Oral Cavity Cancer Analysis of 6830 Cases From the
National Cancer Data Base. Jama Otolaryngology-Head & Neck Surgery 2015;141:593-598.
43. Dionne KR, Warnakulasuriya S, Zain RB, Cheong SC. Potentially malignant disorders of
the oral cavity: Current practice and future directions in the clinic and laboratory. International
Journal of Cancer 2015;136:503-515.
44. Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa—
Diagnostic problems and prognostic features. Current Diagnostic Pathology;12:11-21.
45. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa;
terminology, classification and present concepts of management. Oral Oncology 2009;45:317323.
46. Pindborg J, Reichart P, Smith C, Van der Waal I. World Health Organization International
Histological Classification of Tumours. Histological typing of cancer and precancer of the oral
mucosa. Berlin: Springer, 1997.
47. Ho MW, Risk JM, Woolgar JA, Field EA, Field JK, Steele JC, Rajlawat BP, Triantafyllou
A, Rogers SN, Lowe D, Shaw RJ. The clinical determinants of malignant transformation in
oral epithelial dysplasia. Oral Oncology 2012;48:969-976.
48. Scully C. Challenges in predicting which oral mucosal potentially malignant disease will
progress to neoplasia. Oral Diseases 2014;20:1-5.
49. Arduino PG, Bagan J, El-Naggar AK, Carrozzo M. Urban legends series: oral leukoplakia.
Oral Diseases 2013;19:642-659.
50. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, Eisenberg E,
Krutchkoff DJ, Cushing M. Intraexaminer and interexaminer reliability in the diagnosis of oral
epithelial dysplasia. Oral surgery, oral medicine, oral pathology, oral radiology, and
endodontics 1995;80:188-191.
51. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral
premalignant lesions. Oral Oncology 2006;42:461-474.
52. Potter TJ, Summerlin DJ, Campbell JH. Oral malignancies associated with negative
transepithelial brush biopsy. Journal of Oral and Maxillofacial Surgery 2003;61:674-677.
21

53. Kerker M. The scattering of light, and other electromagnetic radiation. Academic Press,
1969.
54. Hollas JM. Modern Spectroscopy. West sussex, England: John Wiley and Sons, 2004:483.
55. Puppels GJ, Demul FFM, Otto C, Greve J, Robertnicoud M, Arndtjovin DJ, Jovin TM.
Studying single living cells and chromosomes by confocal Raman microspectroscopy. Nature
1990;347:301-303.
56. Kastanos EK, Kyriakides A, Hadjigeorgiou K, Pitris C. A novel method for urinary tract
infection diagnosis and antibiogram using Raman spectroscopy. Journal of Raman
Spectroscopy 2010;41:958-963.
57. Buschman HP, Motz JT, Deinum G, Romer TJ, Fitzmaurice M, Kramer JR, van der Laarse
A, Bruschke AV, Feld MS. Diagnosis of human coronary atherosclerosis by morphology-based
Raman spectroscopy. Cardiovascular Pathology 2001;10:59-68.
58. Pilotto S, Pacheco MTT, Silveira L, Villaverde AB, Zangaro RA. Analysis of near-infrared
Raman spectroscopy as a new technique for a transcutaneous non-invasive diagnosis of blood
components. Lasers in Medical Science 2001;16:2-9.
59. Tu Q, Chang C. Diagnostic applications of Raman spectroscopy. NanomedicineNanotechnology Biology and Medicine 2012;8:545-558.
60. Driskell JD, Kwarta KM, Lipert RJ, Porter MD, Neill JD, Ridpath JF. Low-level detection
of viral pathogens by a surface-enhanced Raman scattering based immunoassay. Analytical
Chemistry 2005;77:6147-6154.
61. Chan JW, Taylor DS, Zwerdling T, Lane SM, Ihara K, Huser T. Micro-Raman spectroscopy
detects individual neoplastic and normal hematopoietic cells. Biophysical Journal
2006;90:648-656.
62. Haka AS, Shafer-Peltier KE, Fitzmaurice M, Crowe J, Dasari RR, Feld MS. Diagnosing
breast cancer by using Raman spectroscopy. Proceedings of the National Academy of Sciences
of the United States of America 2005;102:12371-12376.
63. Lyng FM, Faolain EO, Conroy J, Meade AD, Knief P, Duffy B, Hunter MB, Byrne JM,
Kelehan P, Byrne HJ. Vibrational spectroscopy for cervical cancer pathology, from
biochemical analysis to diagnostic tool. Experimental and Molecular Pathology 2007;82:121129.
64. Grubisha DS, Lipert RJ, Park HY, Driskell J, Porter MD. Femtomolar detection of prostatespecific antigen: An immunoassay based on surface-enhanced Raman scattering and
immunogold labels. Analytical Chemistry 2003;75:5936-5943.
65. Li SX, Zhang YJ, Xu JF, Li LF, Zeng QY, Lin L, Guo ZY, Liu ZM, Xiong HL, Liu SH.
Noninvasive prostate cancer screening based on serum surface-enhanced Raman spectroscopy
and support vector machine. Applied Physics Letters 2014;105.

22

66. Connolly JM, Davies K, Kazakeviciute A, Wheatley AM, Dockery P, Keogh I, Olivo M.
Non-invasive and label-free detection of oral squamous cell carcinoma using saliva surfaceenhanced Raman spectroscopy and multivariate analysis. Nanomedicine-Nanotechnology
Biology and Medicine 2016;12:1593-1601.
67. Lui H, Zhao J, McLean D, Zeng H. Real-time Raman Spectroscopy for In Vivo Skin Cancer
Diagnosis. Cancer Research 2012;72:2491-2500.
68. Shim MG, Song L, Marcon NE, Wilson BC. In vivo near-infrared Raman spectroscopy:
Demonstration of feasibility during clinical gastrointestinal endoscopy. Photochemistry and
Photobiology 2000;72:146-150.
69. Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Lyons J, Hicks D, Fitzmaurice M, Dasari
RR, Crowe JP, Feld MS. In vivo margin assessment during partial mastectomy breast surgery
using Raman spectroscopy. Cancer Research 2006;66:3317-3322.
70. Smits RWH, Koljenovic S, Hardillo JA, ten Hove I, Meeuwis CA, Sewnaik A, Dronkers
EAC, Schut TCB, Langeveld TPM, Molenaar J, Hegt VN, Puppels GJ, de Jong RJB. Resection
margins in oral cancer surgery: Room for improvement. Head and Neck-Journal for the
Sciences and Specialties of the Head and Neck 2016;38:E2197-E2203.
71. Cals FLJ, Schut TCB, Hardillo JA, de Jong RJB, Koljenovic S, Puppels GJ. Investigation
of the potential of Raman spectroscopy for oral cancer detection in surgical margins.
Laboratory Investigation 2015;95:1186-1196.
72. Barroso EM, Smits RWH, van Lanschot CGF, Caspers PJ, ten Hove I, Mast H, Sewnaik
A, Hardillo JA, Meeuwis CA, Verdijk R, Hegt VN, de Jong RJB, Wolvius EB, Schut TCB,
Koljenovic S, Puppels GJ. Water Concentration Analysis by Raman Spectroscopy to
Determine the Location of the Tumor Border in Oral Cancer Surgery. Cancer Research
2016;76:5945-5953.
73. Malik A, Sahu A, Singh SP, Deshmukh A, Chaturvedi P, Nair D, Nair S, Krishna CM. In
vivo Raman spectroscopy-assisted early identification of potential second primary/recurrences
in oral cancers: An exploratory study. Head and Neck-Journal for the Sciences and Specialties
of the Head and Neck 2017;39:2216-2223.
74. Schut TCB, Witjes MJH, Sterenborg H, Speelman OC, Roodenburg JLN, Marple ET,
Bruining HA, Puppels GJ. In vivo detection of dysplastic tissue by Raman spectroscopy.
Analytical Chemistry 2000;72:6010-6018.
75. Carvalho LFCS, Bonnier F, O'Callaghan K, O'Sullivan J, Flint S, Byrne HJ, Lyng FM.
Raman micro-spectroscopy for rapid screening of oral squamous cell carcinoma. Experimental
and Molecular Pathology 2015;98:502-509.
76. Malini R, Venkatakrishna K, Kurien J, Pai KM, Rao L, Kartha VB, Krishna CM.
Discrimination of normal, inflammatory, premalignant, and malignant oral tissue: A Raman
spectroscopy study. Biopolymers 2006;81:179-193.

23

77. Li Y, Wen ZN, Li LJ, Li ML, Gao N, Guo YZ. Research on the Raman spectral character
and diagnostic value of squamous cell carcinoma of oral mucosa. Journal of Raman
Spectroscopy 2010;41:142-147.
78. Guze K, Pawluk HC, Short M, Zeng H, Lorch J, Norris C, Sonis S. Pilot study: Raman
spectroscopy in differentiating premalignant and malignant oral lesions from normal mucosa
and benign lesions in humans. Head and Neck-Journal for the Sciences and Specialties of the
Head and Neck 2015;37:511-517.

24

Chapter 2:

Recent advances in optical diagnosis of oral cancers:

review and future perspectives
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2.1

Abstract

Optical diagnosis techniques offer several advantages over traditional approaches, including
objectivity, speed and cost, and these label-free, non-invasive methods have the potential to
change the future work-flow of cancer management. The oral cavity is particularly accessible
and thus such methods may serve as alternate/adjunct tools to traditional methods. Recently, in
vivo human clinical studies have been initiated with a view to clinical translation of such
technologies. A comprehensive review of optical methods in oral cancer diagnosis is presented.
Following an introduction to the epidemiology and aetiological factors associated with oral
cancers currently employed diagnostic methods and their limitations are presented. A thorough
review of fluorescence, infrared absorption and Raman spectroscopic methods in oral cancer
diagnosis is presented. The applicability of minimally invasive methods based on serum and
saliva is also discussed. The review concludes with a discussion on future demands and scope
of developments from a clinical point of view.
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2.2

Oral Cancers: An Overview

Oral squamous cell carcinoma (OSCC) ranks as the 15th most common cancer in the world and
10th most frequent in males. It accounts for ~2.1% of total cancer cases worldwide. Incidence
rates are high among males in south central Asia and among females in eastern and central
Europe1. Although mortality from oral cancer has decreased in the past few decades, it is still
high and has a five year survival rate of 50%77. Several oral lesions and conditions are
associated with an increased potential for malignant transformation. Of these, the most
commonly occurring is leukoplakia, defined as ‘a predominantly white lesion of the oral
mucosa that cannot be characterized as any other definable lesion’ Figure 2.1 (B). A wide range
of malignant transformation rates have been reported, from 0.13-36.478%, depending on the
presence and degree of dysplasia, location in the oral cavity and maturity of the lesion3,4.
Conversely, erythroplakia, defined as ‘a fiery red patch which cannot be characterized
clinically or pathologically as any other definable lesion’3, is less prevalent and has a higher
potential for malignant transformation (14.379-66.780 %)5. Oral submucous fibrosis is a
premalignant oral condition arising mostly due to areca nut or betel quid chewing6. It has a
reported transformation rate of 7.6%6. Oral lichen planus is an inflammatory disease of the oral
mucosa. Like leukoplakia, it presents as a white plaque or patch. However, its malignant
transformation rate is much lower than leukoplakia, ~1%7 Figure 2.1 (C).
A number of risk factors are associated with oral cancer, including cigarette smoking and
alcohol consumption, which are responsible for 42% and 16% of oral cancer deaths
respectively8. The carcinogenicity of cigarette smoke has long been established, resulting in
DNA damage and increase in P53 mutations9. The association between alcohol and oral cancer
was reported to be dose dependent and a number of factors may contribute to its
carcinogenicity, including acetaldehyde, an alcohol metabolite thought to be carcinogenic10.
Moreover, alcohol is thought to act as a solvent for other carcinogens10. Oral habits such as
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smokeless tobacco and betel quid chewing are also implicated in oral cancer development 11.
They are more common in the Asian population; in India, 50% of oral cancers arise due to
smokeless tobacco chewing11. The carcinogenicity of smokeless tobacco arises from the
production of nitrosamines11. Oral squamous cell carcinoma has also been associated with the
Epstein Bar (EBV) and Human Papilloma (HPV) Viruses, although their putative role is
controversial. Around 23% of OSCC were found to be positive for high risk HPV 16 and 18
12

.

Figure 2.1 Clinical presentation of (A), tongue cancer (B) leukoplakia and (C) lichen planus
2.2.1

Current Screening/Diagnostic methods and limitations:

Screening tests or diagnostic aids presently available for oral cancer include conventional oral
examination (COE), staining with toluidine blue, oral brush biopsy and scalpel biopsy coupled
with histology.
2.2.2

Conventional Oral Examination (COE):

Conventional oral examination (COE), using normal (incandescent) light, has long been the
standard screening method for oral abnormalities. As it is a visual method, it cannot identify
early mucosal abnormalities that may or may not lead to oral cancer. Approximately 5-15% of
the general population has oral mucosal abnormalities and the vast majority of these lesions
are benign in nature 13, Furthermore, only a small percentage of leukoplakias are progressive
or become malignant and COE cannot discriminate between these and their non-progressive
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counterparts. Therefore, while COE may be useful in discovering some oral lesions, its
potential in identifying all potentially premalignant or biologically relevant lesions that are
likely to progress to cancer is questionable.
2.2.3

Toluidine blue staining

Toluidine blue (TB), has been used for more than 40 years as an aid to detection of mucosal
abnormalities of the cervix and the oral cavity. TB is a metachromatic, acidophilic dye that
binds preferentially to tissues undergoing rapid cell division (inflammatory, regenerative and
neoplastic tissue), resulting in preferential staining of abnormal tissue. Overall, TB appears to
be useful in detecting carcinomas, but is positive in only ~50% of lesions with dysplasia. In
addition, it frequently stains common, benign conditions such as non-specific ulcers. The high
rate of false positive stains and the low specificity in staining dysplasia are some of the accepted
limitations of the technique 14.
2.2.4

Oral brush biopsy

Oral brush biopsy extracts a complete trans-epithelial biopsy specimen, with cellular
representation from each of the three layers (basal, intermediate and superficial). Because the
brush biopsy detects only cellular atypia, positive results must be confirmed with a scalpel
biopsy for definitive diagnosis. This technique has therefore been criticized for adding time
and cost to the diagnosis of oral lesions without additional benefit to the patient 15. Overall, it
is a method of identifying unsuspected oral cancers found during a visual examination, at early
and curable stages16.
2.2.5

Histology

Histological risk stratification, currently the gold standard for oral cancer diagnosis, requires
biopsy, staining and microscopic examination by a pathologist17. However, removal of tissue
or biopsy is an inherently invasive procedure and carries risk of complications in the proximity
of vital anatomy. Sampling errors in collecting or interpreting biopsies due to inter-observer
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discrepancy can be significant. Once removed, the tissue can undergo biochemical changes
which can lead to artifacts. In many diseases, tissue involvement is not uniform, potentially
leading to sampling errors. Especially in oral cancers, some early lesions are clinically
indistinguishable from benign conditions. Furthermore, histologically, identification of subtle
changes in precancerous lesions or in normal mucosa that are indicative of early neoplastic
transformation is subjective and can lead to inter-observer variations 18.
It is therefore conceivable that the primary prevention of the disease would involve activities
to reduce or eliminate the use of tobacco and alcohol. Secondary prevention includes activities
that are aimed to detect the disease at an early stage which would lead to better prognosis and
lower morbidity. Current methods of detection of oral cancers are based largely on visual
observations of abnormalities in tissue or cellular morphology and are therefore limited in
terms of sensitivity and specificity, particularly at early stages. In the following section, a
general discussion on the application of optical spectroscopic methods as an alternate/adjunct
diagnostic tool for oral cancer is presented.

2.3

Optical spectroscopy in oral cancer diagnosis

Spectroscopy is the study of the frequency dependence of the interaction of electromagnetic
radiation (light) with matter. Generally, light interacts with matter through absorption, emission
and scattering/reflection. In each case, the spectrum of the interaction gives information about,
and is characteristic of, the structure and chemical content of the sample. Optical measurements
provide quantitative information based on the spectroscopic signature of the biochemical
constituents of the sample that can be rapidly analyzed to yield an objective diagnosis, even in
the hands of a non-expert operator. Diagnosis is based on biochemical changes underlying the
pathology rather than visual or microscopic changes in cellular or tissue morphology. Devices
to make these measurements have become inexpensive, robust, and portable, because of
advances in computing, optical, fiber-optical, and semiconductor technology. Approaches
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based on fluorescence, Fourier-transform infrared absorption and Raman scattering
spectroscopy have shown potential for improved detection of oral cancers. A brief introduction
of these techniques and their potential applications in oral cancer diagnosis is presented in the
following sub-sections. Figure 2.2 provides a schematic illustration of their typical method of
application.

Figure 2.2 A schematic of the typical application of optical spectroscopic techniques for
diagnostic applications.
The light source is delivered via a probe or microscope (for in-vivo or ex vivo/in-vitro
applications respectively) to the sample (cells, tissue or biofluid). Upon excitation by an
appropriate source, molecules can either; go to an excited state and reemit light in the form of
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fluorescence (UV/visible lamp), absorb the light to generate vibrations within the molecules
(Infrared lamp), or, by interaction with the vibrational modes of the molecules in the cells; the
light is Raman scattered (visible or near infrared laser). The emitted/transmitted/scattered light
is then collected by the probe or microscope and passed to a detector. The operator can then
perform analysis on the resulting spectra and, using a prepared classifier, the output can for
example be a yes, no, or maybe for the presence of cancer. The technique can be modified
according to the application; in-vivo, ex-vivo (histological or cytological) or in vitro.
2.3.1

Fluorescence spectroscopy

When a molecule is illuminated at an excitation wavelength lying within the absorption
spectrum of that molecule, it absorbs the energy and undergoes a transition from the ground
state to an excited state. The molecule can then relax back from the excited state to the ground
state by emission of light at specific emission wavelengths. In the UV/visible/Near infrared
region of the spectrum (~200-1000nm), light emission takes the form of fluorescence (or
occasionally phosphorescence). A fluorescence emission spectrum represents the fluorescence
intensity measured over a range of emission wavelengths at a fixed excitation wavelength and
can provide information relating to the molecular characteristics of the fluorophore, Figure 2.3.
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Figure 2.3 Comparison of typical fluorescence spectrum (riboflavin) and typical Raman
spectrum of tissue (both normalised) plotted on an energy scale.
The intrinsic bandwidth of the fluorescence feature is very broad, compared to the Raman
spectrum, which has a multitude of narrow bands which are shifted from the source wavelength
of 785nm (~1.6eV). The energy shift of the Raman band is a measure of the vibrational energy
and for comparison with infra-red spectroscopy is usually expressed in wavenumbers (1/cm).
Note the energy scales for the two spectra are different.

In the late 1970s, cancer diagnosis based on auto-fluorescence (also called natural, intrinsic or
endogenous fluorescence) of naturally occurring fluorophores such as collagen, elastin, keratin
and NADH was initiated 19. The presence of disease can lead to changes in blood concentration,
nuclear size, collagen content or epithelial thickness, which can alter the concentration and
characteristics of the fluorophores. In oral cancers, it was demonstrated that the epithelial layer
shields the strongly fluorescing collagen layer leading to a low intensity of fluorescence in
cancers20. An ex vivo study used hamster buccal pouch as an experimental model to identify
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spectral markers associated with different stages of oral carcinogenesis

21

. Onizawa et al.,

compared fluorescence spectra from human and hamster biopsies and oral cancer cell lines,
suggesting that variation in the riboflavin and porphyrin fluorescence can be used as a
spectroscopic marker for normal and cancerous conditions22. Ingrams et al. further showed that
normal and cancerous human biopsies can be discriminated based on their autofluorescence
spectral profile23. Another ex vivo study by Muller et al., explored the feasibility of quantifying
the spectroscopic response of different grades of malignancy24.
The first in vivo study using autofluorescence spectroscopy by Harris et al. reported differences
between healthy and tumor mucosa based on the porphyrin emission band25. These differences
were attributed to microorganisms living on ulcerating or necrotic surfaces. In vivo methods
have also been explored to understand oral cancer progression in animal models26. Gillenwater
et al. recorded in vivo autofluorescence from oral mucosa of 8 healthy volunteers and 15
patients with premalignant or malignant lesions27. Decreased intensity in the blue spectral
regions, and increased porphyrin fluorescence in the red were observed. Based on the ratio
between these, a sensitivity of 82% and specificity of 100% were reported
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. Various other

studies have provided further evidence in support of in vivo fluorescence spectroscopy for noninvasive oral cancer diagnosis28-30. A recent study by Shaizu et al. showed that
autofluorescence spectroscopy can be used to identify oral cavity disorders caused by longterm tobacco habits. Their findings suggest that lower collagen levels and increased ratios of
flavin adenine dinucleotide (FAD) to nicotinamide adenine dinucleotide (NADH) can serve as
prognostic markers for oral cancer risk 31.
However, tissue contains few natural fluorophores and their spectroscopic features are broad
and overlapping, making them poorly distinguishable, reducing the specificity of fluorescence
spectroscopy for diagnostic applications.
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2.3.2

Fourier-transform infrared spectroscopy

Vibrational Spectroscopy is a subset of spectroscopy which analyses vibrations within a
molecule (or material). The vibrations are characteristic of the molecular structure and, in
polyatomic molecules, give rise to a spectroscopic “fingerprint”. The spectrum of vibrational
energies or frequencies (expressed as wavenumbers, cm-1) can thus be employed to characterise
a molecular structure, or changes to it due to the local environment or external factors
(radiation, chemical agents). Vibrational energies fall within the mid Infrared (IR) region of
the electromagnetic spectrum and are commonly probed through IR absorption spectroscopy.
High energy or frequency vibrations are characteristic of light, tightly bound groups such as CH, N-H and O-H, whereas low frequencies are associated with heavier groups, or collective
vibrations such as ring breathing or skeletal stretches in macromolecules (Figure 2.4).
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Figure 2.4 Comparison of typical IR absorption and Raman spectra of human tissue samples.
The IR spectrum is in the mid infrared region of the spectrum, and the spectrum is less rich in
information than the Raman spectrum. The Raman spectrum is expressed as wavenumber shift
from the source laser line, although as shown in Figure 2.3, the scattered light is in the visible
region of the spectrum. Both show typical features of lipids (●), proteins (▲), carbohydrates
(■) and nucleic acids (♦). Note the strong absorption due to trace water in the FTIR spectrum
in the region of ~3300cm-1.

IR spectroscopy is now a routine technique for materials characterisation and has found
numerous applications in forensics, environmental science and pharmacology32. Applications
to tissue samples for (cancer) diagnostic applications were first reported in the early 90s, and
since this time a range of pathologies has been investigated33.
Wu et al. demonstrated that, on the basis of lipid and protein content, normal and tumor oral
tissues can be discriminated34. In another study, of 10 normal sub-gingival tissues (NST) and
15 oral squamous cell carcinoma (SCC) tissues, Fukuyama et al. demonstrated that the normal
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spectra are strongly influenced by the presence of collagen. They also suggested that spectra
are influenced by keratin, which exists in the ectodermal cells35. A study using FTIR
spectroscopy to understand oral carcinogenesis in animal models have also been reported
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.

FTIR imaging methods have also been explored to analyze different aspects of oral cancers. A
study by Schultz et al., to assess changes in biochemistry of well and poorly differentiated
oral/oropharyngeal SCC by infrared microspectroscopy, demonstrated that DNA and keratin
can provide spectral markers to differentiate between normal and SCC biopsies37. Bruni et al.,
by generating three-dimensional IR chemical maps, demonstrated that proliferating and
regressive states of head and neck tumours can be identified38. Towards high throughput,
automated analysis, Pallua et al. demonstrated that good quality FTIR images can be obtained
from formalin fixed paraffin embedded tissue microarray sections providing molecular level
information as the basis for diagnosis39.
Compared to fluorescence, FTIR provides a detailed fingerprint of the biochemical content of
the sample. However, although FTIR has been used for the analysis of human tissues ex vivo,
the application of this method for in vivo diagnosis is limited, due to the short penetration depth
and the fact that water is highly absorptive in the mid-IR range. Conventional optical fibres
have limited transparency in the IR region, and therefore, in vivo studies are less frequent than
fluorescence or Raman fibre optical applications. New developments based on attenuated total
reflection (ATR) elements might help in implementing in vivo applications.

2.3.3

Raman spectroscopy

Raman spectroscopy is a complementary technique to FTIR and has its origin in the discovery
of the Raman effect in 1928, for which C.V. Raman was awarded the Nobel prize in 1930 40.
Similar to IR spectroscopy, Raman entails the coupling of incident radiation with molecular
vibrations and the resultant spectrum is similarly characteristic of the material. However,
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whereas IR spectroscopy involves the absorption of radiation, Raman spectroscopy is a
scattering technique, whereby the incident radiation couples with the vibrating polarisation of
the molecule and thus generates or annihilates a vibration. The differing underlying
mechanisms results in a complementarity of the techniques. Vibrations of asymmetric, polar
bonds thus tend to be strong in IR spectra, whereas Raman is particularly suitable as a probe
of symmetric, nonpolar groups. Notably, O-H vibrations of water are very strong in IR spectra,
but are extremely weak in Raman spectra, rendering Raman a potentially more suitable
technique for in vivo applications Figure 2.3. A further implication of the differing physical
origins of the techniques is that, whereas IR monitors the absorption of IR radiation, Raman
scattering can be employed in the UV, visible or near IR regions of the spectrum Figure 2.2.
Raman scattering thus offers intrinsically higher spatial resolution for mapping or profiling in
a confocal microscopy mode, the limit of spatial resolution being determined by the wavelength
(<1µm for Raman, ~5-10 µm for IR). The application of Raman spectroscopy to biomolecules
was first demonstrated as early as the 1960s and by the 1970s biomedical applications were
explored41. Whole cell, tissue and in vivo studies carried out on a range of pathologies have
demonstrated the potential for diagnostic applications42.
Raman spectroscopic applications in oral cancer diagnostics started with the analysis of normal
and dysplastic tissue in a rat model by Schut et al. (2000). Dysplasia in the palate was induced
by topical application of the carcinogen 4-nitroquinoline 1-oxide and sensitivity and specificity
of 100% were observed43. This was followed by a study of human oral cancer biopsies by
Venkatakrishna et al, they recorded spectra of 49 biopsies and obtained an average
classification efficiency of 88%44. In 2004, a study carried out by Krishna et al. demonstrated
the applicability of formalin fixed oral tissues for optical pathology, revealing significant
differences in the epithelial region of normal and malignant samples, arising from the protein
composition, conformational/structural changes, and possible increase in protein content in
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malignant epithelia45. In 2006, Malini et al. demonstrated the efficacy of Raman spectroscopic
methods in discriminating normal, cancerous, precancerous and inflammatory conditions46.
Lipid rich features in normal conditions and prominent protein features in tumors and other
pathological conditions were observed. Classification between different groups using
multivariate statistical methods produced 100% sensitivity and specificity46. Raman mapping
of tissue sections further elucidated biochemical changes within different epithelial layers
which are associated with disease onset47. A study by Sunder et al. demonstrated that oral
carcinomas of different pathological grades can also be differentiated on the basis of the
relative intensities of bands associated with lipids and proteins48.
In vivo Raman spectroscopy using fibreoptic probes for identifying site specific
variations in the oral cavity was reported by Guze et al. in 2009, indicating that different oral
sites can be discriminated on the basis of level of keratinization49. Bergholt et al., (2011),
characterized the Raman spectroscopic profiles of different oral cavity regions (inner lip,
attached gingiva, floor, dorsal tongue, ventral tongue, hard palate, soft palate, and buccal
mucosa)50. Fitting of reference biochemicals (hydroxyapatite, keratin, collagen, DNA, and
oleic acid) and partial least squares-discriminant analysis (PLS-DA) were employed to assess
the inter-anatomical variability. The findings suggest that histological and morphological
characteristics of different sites have a significant influence on the in vivo Raman spectra, and
different sites can be classified with an overall sensitivity and specificity of 85%50 . Singh et
al. demonstrated that in vivo spectra can be acquired in clinically implementable timescales
and demonstrated the feasibility of classification of normal and pathological conditions51. This
was followed by another study exploring tobacco induced cancer field effects in the oral
mucosa52. Sahu et al. demonstrated that in vivo Raman spectroscopy methods can also be
utilized to understand age-related changes in the oral mucosa53. These findings were further
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verified by a recent study showing anatomical variability and feasibility of identifying
pathological conditions with in vivo Raman spectroscopy 54.

2.4

Minimally invasive methods in oral cancer diagnosis

Bio fluids such as blood, urine, lymph, and saliva can provide substantial information about
human health and are being widely investigated for clinical diagnosis of various diseases
including oral cancers. The attraction of these specimens lies in the fact that they can be used
for mass screening, due to ease in collection, transport and low cost55. Studies have been carried
out on physiochemical properties of saliva using surface enhanced laser desorption and
ionization time of flight (SELDI-TOF) coupled with mass spectrometry (MS) and high
performance liquid chromatography (HPLC) to identify proteomic and enzymatic markers
associated with oral cancer56. Other techniques such as laser-induced fluorescence coupled
with HPLC, and capillary electrophoresis coupled mass spectroscopy have been employed to
characterise salivary metabolites in oral cancer patients57,58.
Recently, optical methods based on Raman, infrared absorption, and ﬂuorescence
spectroscopies have also been exploited for such investigations. For example, enhanced levels
of porphyrin in blood have been used as a diagnostic marker for various cancers including oral
cancers59,60. Yuvaraj et al. characterized different salivary metabolites associated with oral
cancers by fluorescence spectroscopy61. FTIR spectroscopy has been applied to study sputum
in order to diagnose oral cancers and discrimination between normal and cancerous samples
was achieved on the basis of changes in the protein and glycoprotein structure within cells 62.
Surface-Enhanced Raman spectroscopy methods (SERS) have been used to differentiate
between normal and oral cancer patients using spectra acquired from saliva63. A recent study
by Elumalai et al. demonstrated that Raman spectroscopy of urine samples of healthy subjects
and oral cancer patients can offer potential diagnostic information with a discrimination
accuracy of 94%64. The analysis of exfoliated oral cells by optical methods also holds enormous
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promise for early disease detection and diagnosis. Diem and co-workers have carried out
multiple studies on spectral cytopathology of oral exfoliated cells65,66. Their findings are
suggestive of the tremendous potential of spectroscopic methods in identifying minor changes
associated with disease onset. Nevertheless, diagnosis based on biofluids suffers from
limitations such as low analyte concentration, longer acquisition time, prone to experimental
errors etc. Considerable efforts have been undertaken to develop standard protocols and
sensitive instrumentation. Signal enhancements with the help of nano-particles or surface
coating is an active area of research
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. Concentration of samples using centrifugal filtration

devices has been shown to offer an alternative which allows measurement of the analytes in
the native aqueous environment68. This also allows fractionation according to molecular weight
of the constituent analytes, potentially allowing the targeting of molecular biomarkers of a
disease. Appropriate modification of the instrumentation, especially automation for collection
and analysis of body fluids is also an area which requires constant development. Efforts should
also be undertaken for large scale trials and database development to overcome inter-laboratory
and instrument variabilities 69.

2.5

Summary and Outlook

Although the oral cavity is easily accessible to inspection, oral cancer patients often present at
an advanced stage when treatment is less successful, thereby leading to high morbidity and
mortality. Early detection is the best way to ensure patient survival and quality of life. The
current gold standard for clinical diagnosis of oral lesions is biopsy and subsequent
histopathological confirmation. The process is invasive, time-consuming and prone to interobserver variability. An alternate method of diagnosis that can enable non-invasive diagnosis
of the oral cavity in individuals with suspicious oral lesions is warranted.
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It is now well recognized that techniques based on optical spectroscopy can play a very
important role towards this end. Spectroscopic measurements of tissue biochemistry, with
sensitivity and specificity to localize changes enhanced by imaging, represent a measure of
health (or disease) unattainable in current practice, and can provide sensitivities for early stage
detection of biochemical, rather than simply morphological, abnormalities. Table 1 lists the
advantages and disadvantages of the current screening/diagnostic methods and optical
spectroscopy methods. Among the spectroscopic techniques described, fluorescence is perhaps
the most technologically accessible, as it is simply based on the analysis of light which is
emitted after illumination with a UV lamp. The emitted light is in the visible range and
therefore probes can use free space or low grade, inexpensive fibre optics. The technique
detects only the small fraction of endogenous biomolecules which are fluorescent, however,
and relies on identifying pathology specific biomarkers amongst them. FTIR spectroscopy, on
the other hand, produces a label free fingerprint of the complete biochemical content of the
tissue, cell or biofluid, and this can explore more global and specific pathological changes.
However, water is an extremely strong FTIR absorber, and so in vivo diagnostic applications
may be limited. Raman spectroscopy provides a similar complete, label free fingerprint of the
sample, and also couples to benefits of working in the visible region of the spectrum. Water is
a weak Raman scatterer, and so the technique is more adaptable to routine in vivo patient
screening or ex vivo spectral histology or cytology. The prospect is therefore of a high
sensitivity and specificity, automatable, objective quantitative label free probe of early stage
disease development and progression, based on the biomolecular content of the patient sample.
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Table 2-1 Advantages and disadvantages of current screening / diagnostic methods and optical
spectroscopy methods
Technique
Conventional
oral
examination

Advantages
Well accepted screening method
No instrumentation or reagents
required
Rapid

Toluidine
Blue staining

No instrumentation required
Rapid

Oral brush
biopsy

Less invasive method for transepithelial biopsy
Rapid

Histology

Well accepted gold standard method
Definitive diagnosis of tumour stage
Stromal invasion can be determined
Tumour margins can be determined

Fluorescence
spectroscopy

Objective
Can be used by non-specialists with
suitable diagnostic algorithms
No reagents required as based on
intrinsic fluorescence of
fluorophores such as collagen,
elastin, keratin and NADH
Can be used ex vivo or in vivo
Can be used for cells, tissues and
biofluids
Objective
Can be used by non-specialists with
suitable diagnostic algorithms
No reagents required as based on a
fingerprint of the biochemical
composition

Infra Red
spectroscopy

42

Disadvantages
Subjective
Requires clinical expertise and
experience
Unable to identify potentially premalignant lesions
Subjective
Requires clinical expertise and
experience
Reagents required
Low specificity for dysplasia
Subjective
Requires clinical expertise and
experience
Reagents and instrumentation
required
Must be confirmed with scalpel
biopsy and histology
Subjective
Requires clinical expertise and
experience
Pre-malignant lesions difficult to
distinguish from benign conditions
Reagents and instrumentation
required
Invasive
Inter-observer variations
Sampling errors
Slow
Instrumentation required
Low specificity due to relatively
few natural fluorophores with
broad, overlapping features

Instrumentation required
Limited use in vivo due to short
penetration depth and interference
from water

Raman
spectroscopy

Mainly used ex vivo but in vivo may
be possible using ATR-FTIR
spectroscopy
Can be used for cells, tissues and
biofluids
Short spectral acquisition times
Objective
Can be used by non-specialists with
suitable diagnostic algorithms
No reagents required as based on a
fingerprint of the biochemical
composition
Can be used ex vivo or in vivo
Can be used for cells, tissues and
biofluids
High spatial resolution allowing
subcelluar imaging
Increased penetration depth using
SORS

Low spatial resolution but can be
improved with ATR-FTIR
spectroscopy
Multivariate data analysis needed
to extract information from the
spectral data
Instrumentation required
Long spectral acquisition times
Multivariate data analysis needed
to extract information from the
spectral data

Variable thickness and degree of keratinisation at different sites in the oral cavity can
influence the diagnostic efficacy of optical methods, especially for early lesions. This issue has
been addressed extensively by the biomedical spectroscopic community. Various studies have
successfully demonstrated the potential of spectroscopic methods in identifying anatomical
variability due to different levels of keratinization. For example, a study by Rupananda et al.
showed a higher fluorescence due to porphyrins in the tongue compared to other oral sites 29,
while Guze et al found that Raman spectra can be clustered according to sites in the oral cavity
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. Similar findings were reported by Bergholt et al., who found that the sites clustered into three

groups; (1) buccal, inner lip, and soft palate; (2) dorsal, ventral tongue, and floor; (3) gingiva and
hard palate 50. These studies have provided evidence in support of inherent differences between

different locations and suggested that each site be treated independently. For example, spectral
models developed using spectra from buccal mucosa cancers cannot be used for identifying
abnormalities at tongue or palate. Most of the recent studies have been performed under these
guidelines, where tumours of specific sites are treated separately51-54. As with all optical
techniques, the depth sensitivity is limited by the absorption and scattering of the tissue.
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Operation in the near infrared can optimise the depth sensitivity of Raman probes, and novel
methodologies such as spatially offset Raman spectroscopy (SORS) promise increased
penetration depths of several millimetres for deeper set lesions 70. Such technological advances
potentially place Raman ahead of the field as candidate for in vivo optical diagnostic
applications.
In the coming years, large scale clinical trials must be conducted to gain the amount of
site-specific data necessary for developing adequate size training and test sets for robust
algorithm development and analysis. The standard models for each of the individual sites in
the oral cavity should be tested rigorously, preferably double-blinded, as multi-centric studies,
before they are considered for routine use. Several technological advances in terms of
fiberoptic probes and miniaturization of instruments are also required for real time and routine
diagnosis. Efficient suppression of background signal, optimization of collection optics, and
incorporation of miniaturized interference filters in the fiber probes are some of the issues that
are to be addressed effectively. Further improvements in data analysis algorithms are also
required for developing less cumbersome, rapid, unambiguous, objective and user friendly
interfaces from the point of view of routine clinical use where a clinician or a technician can
analyze a given spectrum against all available models to diagnose a case. The prospective
adaptation of optical spectroscopy methods for routine clinical diagnosis would decrease the
number of follow-up clinic visits and patient anxiety by minimizing waiting times for
histopathological diagnosis. The technology poses no known risks to the patients, and therefore
could be a safe alternative/adjunct to the current diagnostic methods.

44

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence
and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int
J Cancer 2014;136:359-386.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol
2009;45:309-316.
3. Pindborg J, Reichart P, Smith C, Van der Waal I. World Health Organization International
Histological Classification of Tumours. Histological typing of cancer and precancer of the
oral mucosa. Berlin: Springer; 1997.
4. Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A
follow-up study of 257 patients. Cancer 1984;53: 563-8.
5. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of
invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
1995;79: 321-9.
6. Murti PR, Bhonsle RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant
transformation rate in oral submucous fibrosis over a 17-year period.
Community Dent Oral Epidemiol 1985;13: 340-1.
7. Silverman S, Jr., Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients
with oral lichen planus: persistence, remission, and malignant association.
Oral Surg Oral Med Oral Pathol 1985;60: 30-4.
8. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S et al.
Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48: 32827.
9. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco
smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.
Oncogene 2002;21: 7435-51.
10. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol. 2006;7:149-156
11. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer.
Lancet Oncol 2008;9: 667-75.
12. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head
and neck squamous cell carcinomas worldwide: a systematic review.
Cancer Epidemiol Biomarkers Prev 2005;14: 467-75.
13. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, Rajan B,
Trivandrum Oral Cancer Screening Study G. Effect of screening on oral cancer mortality
in Kerala, India: a cluster-randomised controlled trial. Lancet 2005;365: 1927-33.

45

14. Gandolfo S, Pentenero M, Broccoletti R, Pagano M, Carrozzo M, Scully C. Toluidine blue
uptake in potentially malignant oral lesions in vivo: clinical and histological assessment.
Oral oncol 2006;42: 89-95.
15. Fist
S.
The
oral
brush
biopsy:
separating
fact
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96: 654-5.

from

fiction.

16. Eisen D, Frist S. The relevance of the high positive predictive value of the oral brush
biopsy. Oral oncol 2005;41: 753-5.
17. Suvarna K, Layton C, Bancroft JD. Bancroft's Theory and Practice of Histological
Techniques. Oxford: Churchill Livingstone, 2012:654.
18. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA et al.
Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80: 188-91.
19. Profio AE, Doiron DR. A feasibility study of the use of fluorescence bronchoscopy for
localization of small lung tumours. Phys Med Biol 1977;22: 949-57.
20. Kolli VR, Savage HE, Yao TJ, Schantz SP. Native cellular fluorescence of neoplastic upper
aerodigestive mucosa. Arch Otolaryngol Head Neck Surg 1995;121: 1287-92.
21. Farwell DG, Meier JD, Park J, Sun Y, Coffman H, Poirier B et al. Time-resolved
fluorescence spectroscopy as a diagnostic technique of oral carcinoma: Validation in the
hamster buccal pouch model. Arch Otolaryngol Head Neck Surg 2010;136: 126-33.
22. Onizawa K, Okamura N, Saginoya H, Yusa H, Yanagawa T, Yoshida H. Analysis of
fluorescence in oral squamous cell carcinoma. Oral oncol 2002;38: 343-48.
23. Ingrams DR, Dhingra JK, Roy K, Perrault DF, Jr., Bottrill ID, Kabani S et al.
Autofluorescence characteristics of oral mucosa. Head Neck 1997;19: 27-32.
24. Muller MG, Valdez TA, Georgakoudi I, Backman V, Fuentes C, Kabani S et al.
Spectroscopic detection and evaluation of morphologic and biochemical changes in early
human oral carcinoma. Cancer 2003;97: 1681-92.
25. Harris DM, Werkhaven J. Endogenous porphyrin fluorescence in tumors. Lasers Surg Med
1987;7: 467-72.
26. Wang CY, Tsai T, Chen HC, Chang SC, Chen CT, Chiang CP. Autofluorescence
spectroscopy for in vivo diagnosis of DMBA-induced hamster buccal pouch pre-cancers
and cancers. J Oral Pathol Med 2003;32: 18-24.
27. Gillenwater A, Jacob R, Ganeshappa R, Kemp B, El-Naggar AK, Palmer JL et al.
Noninvasive diagnosis of oral neoplasia based on fluorescence spectroscopy and native
tissue autofluorescence. Arch Otolaryngol Head Neck Surg 1998;124: 1251-8.

46

28. Chaturvedi P, Majumder SK, Krishna H, Muttagi S, Gupta PK. Fluorescence spectroscopy
for noninvasive early diagnosis of oral mucosal malignant and potentially malignant
lesions. J Cancer Res Ther 2010;6: 497-502.
29. Mallia RJ, Subhash N, Sebastian P, Kumar R, Thomas SS, Mathews A, Madhavan J. In
vivo temporal evolution of ALA-induced normalized fluorescence at different anatomical
locations of oral cavity: application to improve cancer diagnostic contrast and potential.
Photodiagnosis Photodyn Ther 2010;7: 162-75.
30. Schwarz RA, Gao W, Daye D, Williams MD, Richards-Kortum R, Gillenwater AM.
Autofluorescence and diffuse reflectance spectroscopy of oral epithelial tissue using a
depth-sensitive fiber-optic probe. Appl opt 2008;47: 825-34.
31. Nazeer Shaiju S, Ariya S, Asish R, Salim Haris P, Anita B, Arun Kumar G et al. Habits
with killer instincts: in vivo analysis on the severity of oral mucosal alterations using
autofluorescence spectroscopy. J biomed opt 2011;16: 087006.
32. Messerchmidt R., Harthcock M. (1988). Infrared Microscopy, Theory and Applications,
New York, Marcel Dekker
33. Dukor RK. Vibrational Spectroscopy in the Detection of Cancer Handbook of Vibrational
Spectroscopyed.: John Wiley & Sons, Ltd, 2006.
34. Wu JG, Xu YZ, Sun CW, Soloway RD, Xu DF, Wu QG et al. Distinguishing malignant
from normal oral tissues using FTIR fiber-optic techniques. Biopolymers 2001;62: 185-92.
35. Fukuyama Y, Yoshida S, Yanagisawa S, Shimizu M. A study on the differences between
oral squamous cell carcinomas and normal oral mucosas measured by Fourier transform
infrared spectroscopy. Biospectroscopy 1999;5: 117-26.
36. Krishnakumar N, Sulfikkarali NK, Manoharan S, Nirmal RM. Screening of
chemopreventive effect of naringenin-loaded nanoparticles in DMBA-induced hamster
buccal pouch carcinogenesis by FT-IR spectroscopy. Mol Cell Biochem 2013;382: 27-36.
37. Schultz CP, Liu KZ, Kerr PD, Mantsch HH. In situ infrared histopathology of keratinization
in human oral/oropharyngeal squamous cell carcinoma. Oncol Res 1998;10: 277-86.
38. Bruni P, Conti C, Giorgini E, Pisani M, Rubini C, Tosi G. Histological and microscopy FTIR imaging study on the proliferative activity and angiogenesis in head and neck tumours.
Faraday discuss 2004;126: 19-26; discussion 77-92.
39. Pallua JD, Pezzei C, Zelger B, Schaefer G, Bittner LK, Huck-Pezzei VA et al. Fourier
transform infrared imaging analysis in discrimination studies of squamous cell carcinoma.
Analyst 2012;137: 3965-74.
40. Raman C.V. and Krishnan K.S. A change of wavelength in light scattering. Nature 1928:
121,501.
41. Walton AG, Deveney MJ, Koenig JL. Raman spectroscopy of calcified tissue.
Calcif Tissue Res 1970;6: 162-7.
47

42. Hanlon EB, Manoharan R, Koo TW, Shafer KE, Motz JT, Fitzmaurice M et al. Prospects
for in vivo Raman spectroscopy. Phys Med Biol 2000;45: R1-59.
43. Bakker Schut TC, Witjes MJ, Sterenborg HJ, Speelman OC, Roodenburg JL, Marple ET et
al. In vivo detection of dysplastic tissue by Raman spectroscopy. Anal chem 2000;72: 60108.
44. Venkatakrishna K, Kurien J, Keerthilata MP, Valiathan M, Kumar NN, Krishna CM et al.
Optical pathology of oral tissue: A Raman Spectroscopy diagnostic method.
Current Science 2001;80:101-105.
45. Krishna CM, Sockalingum GD, Kurien J, Rao L, Venteo L, Pluot M et al. Micro-Raman
spectroscopy for optical pathology of oral squamous cell carcinoma. Appl Spectrosc
2004;58: 1128-35.
46. Malini R, Venkatakrishna K, Kurien J, Pai KM, Rao L, Kartha VB et al. Discrimination of
normal, inflammatory, premalignant, and malignant oral tissue: a Raman spectroscopy
study. Biopolymers 2006;81: 179-93.
47. Cals FLJ, Bakker Schut TC, Koljenović S, Puppels GJ, de Jong RJB. Method development:
Raman spectroscopy-based histopathology of oral mucosa. J Raman Spectrosc 2013;44:
963-72.
48. Sunder NS, Rao Nirmala N, Kartha VB, Ullas G, Kurien J. Laser Raman spectroscopy: A
novel diagnostic tool for oral cancer. J Orofac Sci.2011;3:15-19.
49. Guze K, Short M, Sonis S, Karimbux N, Chan J, Zeng H. Parameters defining the potential
applicability of Raman spectroscopy as a diagnostic tool for oral disease. J Biomed Opt
2009;14: 014016.
50. Bergholt MS, Zheng W, Huang Z, Characterizing variability in in vivo Raman
spectroscopic properties of different anatomical sites of normal tissue in the oral cavity. J
Raman Spectrosc 2012;43:255-262.
51. Singh SP, Deshmukh A, Chaturvedi P, Krishna CM. In vivo Raman spectroscopic
identification of premalignant lesions in oral buccal mucosa. J Biomed Opt 2012;17:
105002.
52. Singh SP, Sahu A, Deshmukh A, Chaturvedi P, Krishna CM. In vivo Raman spectroscopy
of oral buccal mucosa: a study on malignancy associated changes (MAC)/cancer field
effects (CFE). Analyst 2013;138: 4175-82.
53. Sahu A, Deshmukh A, Ghanate AD, Singh SP, Chaturvedi P, Krishna CM. Raman
spectroscopy of oral buccal mucosa: a study on age-related physiological changes and
tobacco-related pathological changes. Technol Cancer Res Treat 2012;11: 529-41.
54. Krishna H, Majumder SK, Chaturvedi P, Gupta PK. Anatomical variability of in vivo
Raman spectra of normal oral cavity and its effect on oral tissue classification. Biomed
Spectrosc Imaging 2013;2: 199-217.

48

55. Rajasekaran R, Aruna PR, Koteeswaran D, Padmanabhan L, Muthuvelu K, Rai RR et al.
Characterization and diagnosis of cancer by native fluorescence spectroscopy of human
urine. Photochem Photobiol 2013;89: 483-91.
56. Bigler LR, Streckfus CF, Dubinsky WP. Salivary biomarkers for the detection of malignant
tumors that are remote from the oral cavity. Clin. Lab. Med. 2009;29: 71-85.
57. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass
spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancerspecific profiles. Metabolomics 2010;6: 78-95.
58. Venkatakrishna K, Kartha VB, Pai KM, Krishna CM, Ravikiran O, Kurian J et al.
HPLC-LIF for early detection of oral cancer. Current Science 2003;84: 551-57.
59. Meng JW, Wang XJ, Ma HP, Ren XG, Xu XR, Ren WM. Protoporphyrin IX fluorescence
from the plasma of tumor-implanted mouse. J Lumin 1999;83–84: 251-4.
60. Madhuri S, Vengadesan N, Aruna P, Koteeswaran D, Venkatesan P, Ganesan S. Native
fluorescence spectroscopy of blood plasma in the characterization of oral malignancy.
Photochem Photobiol 2003;78: 197-204.
61. Yuvaraj M, Udayakumar K, Jayanth V, Prakasa Rao A, Bharanidharan G, Koteeswaran D
et al. Fluorescence spectroscopic characterization of salivary metabolites of oral cancer
patients. J Photochem Photobiol B 2014;130: 153-60.
62. Menzies GE, Fox HR, Marnane C, Pope L, Prabhu V, Winter S et al. Fourier transform
infrared for noninvasive optical diagnosis of oral, oropharyngeal, and laryngeal cancer.
Transl Res 2014;163: 19-26.
63. Olivo M, Bhuvaneswari R, Keogh I. Advances in Bio-Optical Imaging for the Diagnosis
of Early Oral Cancer. Pharmaceutics 2011;3: 354-78.
64. Elumalai B, Prakasarao A, Ganesan B, Dornadula K, Ganesan S. Raman spectroscopic
characterization of urine of normal and oral cancer subjects. J Raman Spectrosc
2015;46:84-93.
65. Papamarkakis K, Bird B, Schubert JM, Miljkovic M, Wein R, Bedrossian K et al.
Cytopathology by optical methods: spectral cytopathology of the oral mucosa. Lab Invest
2010;90: 589-98.
66. Diem M, Mazur A, Lenau K, Schubert J, Bird B, Miljkovic M et al. Molecular pathology
via IR and Raman spectral imaging. J Biophotonics 2013;6: 855-86.
67. Kah JCY, Kho KW, Lee CGL, Richard CJ, Sheppard, Shen ZX et al. Early diagnosis of
oral cancer based on the surface plasmon resonance of gold nanoparticles. Int J
Nanomedicine 2007;2: 785-98.
68. Bonnier F, Baker MJ, Byrne HJ. Vibrational spectroscopic analysis of body fluids: avoiding
molecular contamination using centrifugal filtration. Anal Methods 2014;6:5155

49

69. Byrne HJ, Baranska M, Puppels GJ, Stone N, Wood B, Gough KM et al. Spectropathology
for the Next Generation: Quo Vadis?. Analyst 2015;140:2066-73.
70. Matousek P, Stone N. Recent advances in the development of Raman spectroscopy for deep
non-invasive medical diagnosis. J Biophotonics 2013; 6: 7–19.

50

Chapter 3:

Use of Raman Spectroscopy for the Study of Cell Cycle

Phase and Biomarker Expression Levels in Oral Squamous Cell
Carcinoma Cells
3.1

Introduction

The cell cycle is a highly regulated process with defined phases. G1 is the phase after the
previous cell division during which the cell grows. The S phase is the DNA synthesis phase, in
which the cell replicates its genetic material. In the G2 phase, transcription and translation are
co ordinated to prepare for Mitosis (M phase). The cell cycle is associated with checkpoints in
which the cell assesses its environment to ensure the conditions are appropriate for cell cycle
progression. There are two checkpoints, one at the G1/S boundary and another at the G2/M
boundary. Deregulation of the cell cycle can result in tumourogenesis1 and is often signalled
by the overexpression of certain biomarkers, as, for example cyclin D1. Cyclin D1is one of a
family of D type cyclins which also include D2 and D3. It is important for the G1 to S phase
transition as it binds with the cyclin dependent kinases 4 and 6 to form an active complex that
phosphorylates and inactivates retinoblastoma protein (RB) promoting cell cycle progression2.
The overexpression of cyclin D1 leads to faster progression from G1 to S phase, which in turn
results in increased proliferation and an increased propensity for the development of mutations.
Cyclin D1 is overexpressed in a number of carcinomas such as breast, oesophageal, ovarian,
hepatocellular, colorectal, and head and neck carcinoma3-8. Another biomarker, Proliferating
cell nuclear antigen (PCNA), required for DNA replication, is synthesised in the late G1 and S
phases of the cell cycle9. It acts as a polymerase clamp as well as a sliding platform for the
recruitment of other replication proteins such as DNA helicase, ligase, nuclease, and histone
chaperones10. Levels of PCNA have been found to correlate with increased dysplasia in oral
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epithelial cells11,12. A thorough understanding of cell cycle dynamics is important for cancer
research and tumour targeting. The ability to monitor the altered expression of biomarkers
could prove valuable in cancer screening.
Flow cytometry has been widely used in the study of cell cycle dynamics, as Propidium iodide
(PI) is commonly used to quantify the DNA content which is characteristic of the cell cycle
phase. Quantitative image analysis which utilizes fluorescent dyes has also been used to
identify certain biomarkers that vary throughout the cell cycle13. Both these techniques rely on
prior knowledge of the biomarkers to be studied and can only give information on a few
biomarkers at a time.
Using inhibitors to arrest the cell cycle at the various phases, previous studies have examined
the use of Raman spectroscopy in the discrimination of the cell cycle phases. Using a prostate
cancer cell line, and fixing the cells at the different cell cycle phases, one study found the
greatest differences between the G2M and G1 phases and slight differences between the G1
and S phases14. Similar findings were made by another study looking at live human
osteosarcoma cells, although, unlike the former, where the differences were dominated by
nucleic acids, proteins and lipids, here the differences were mainly in lipids15. Using one
synchronous cell cycle and analysing fibroblast cells with FTIR spectroscopy in two hour
intervals, one study found that there were differences in the lipid, and nucleic acid profiles at
the different time intervals16. The aforementioned studies combine G2 and M phases of the cell
cycle in the analysis, which was also the approach in this study. This is due to the fact that, in
flow cytometry analysis, which uses DNA fluorescent markers, the phases that can be
distinguished are G0/G1 which make up a Gaussian peak with 1x the DNA content, G2M with
a Gaussian peak of 2x the DNA content and S phase which the population in between G0/G1
and G2M.
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The aim of the present study was to investigate the Raman profiles of oral squamous cell
carcinoma cells at defined phases of the cell cycle and to correlate these with cyclin D1 and
PCNA expression in the cells at the different cell cycle phases as assessed by flow cytometry.
In order to assess whether label free Raman signatures can be correlated with established
biomarkers.

3.2

3.2.1

Materials and Methods

Cell culture

SCC-4 cells (ATCC, Manassas, VA), a human tongue squamous cell carcinoma cell line, were
cultured in DMEM F-12 media (Sigma-Aldrich) supplemented with 10% (v/v) foetal bovine
serum (FBS) (Sigma-Aldrich), 1% (v/v) Penicillin/streptomycin and 400 ng/ml hydrocortisone
(Sigma-Aldrich). They were incubated at 37°C with 5% CO2 and regularly passaged at 80%
confluency to maintain exponential growth. The passage number for the experiments did not
exceed 17. Studies have shown that cells transform at high passage numbers (~40) and show
altered expression of mRNAs involved in regulated secretion adhesion and proliferation.

3.2.2

Cell Synchronisation

A double thymidine block, described previously17, which arrests cells in the S phase of the cell
cycle, was used to synchronise the cells. Excess thymidine inhibits DNA synthesis, thereby
arresting cells in G1, prior to DNA replication, or in S phase. A double thymidine block ensures
that any cells that were in mid or late S phase during the first block will be captured in late G1
or early S phase in the second block. SCC-4 cells were cultured in T-125 flasks, they were
trypsinised at 30% confluency, harvested and counted. The confluency/density of cells affects
their proliferation rate which can slow down at confluency above 50%18. Cells were counted
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using a coulter counter, 500,000 cells were seeded into a T-25 flask with 5 ml medium.
Thymidine was added to the flasks to a concentration of 2 mM and incubated with the cells for
18 hours. The cells were then washed with PBS and fresh media was added to release them
from the Thymidne block, they were then incubated for 9 hours. 2mM Thymidine was then
added to the flasks for a second thymidine block and the cells were incubated for 17 hours.
The selected time points were; at time of release from thymidine (0 hours), 6 hours after release,
and 12 hours after thymidine release. The controls were unsynchronised cells (not treated with
thymidine), unstained cells (no primary or secondary antibody), negative control cells (no
primary antibody) and cells with no PI. All time points and controls were completed in
triplicate. Experiments were performed for detecting both cyclin D1 and PCNA.

M

6 hours

6 hour
time point

6 hours

G1

G2

S

6 hours

0 hour time
point
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12 hour
time point

Thymidine
block

Figure 3.1 A schematic of the SCC4 cell cycle. SCC4 cells have an 18 hour cycle (doubling
time) and spend 6 hours in each of the phases (G1, S, and G2M). The thymidine block arrests
the cells at the G1/S boundary so when cells are released they enter S phase.
3.2.3

Flow Cytometry

Cells were harvested by trypsinisation, washed with PBS, then resuspended in ice cold
methanol and stored at 4°C overnight. The fixed cells were pelleted and the pellet was dried to
remove the methanol. The cells were then permeabilised with 0.2% Triton X-100 (BDH) in
PBS (v/v), washed with PBS, then treated with a primary antibody; for cyclin D1, monoclonal
rabbit antihuman cyclin D1 antibody (Dako) (1:50 dilution in PBS) and for PCNA, a mouse
monoclonal [PC10] to PCNA (abcam) (1:50 dilution in PBS). After another PBS wash, for
cyclin D1 detection, an anti-rabbit IgG Fluorescein isothiocyanate (FITC) conjugated antibody
(Sigma-Aldrich) (1:100 dilution in PBS) was incubated with the cells and for PCNA detection
a goat Anti-mouse IgG Alexa Fluor conjugated antibody (abcam) (1:100 dilution in PBS) was
used. Subsequently, the cells were re-suspended in 0.5 ml of PI-RNase (BD Biosciences) and
analysed with a BD Accuri C6 flow cyctometer. The threshold was set at 10,000 events and,
using forward and side scatter characteristics, gates were set to exclude cell debris. The controls
were used to determine the quadrants by determining positive signal from background
fluoresence so the threshold for positivity could be set accordingly. PI and FITC/Alexa Flour
were plotted in the y and x axis respectively so that cells in the lower left quadrant were
negative for both and those in the upper right quadrant were positive for both. Cell cycle phase
was determined by DNA content; PI intercalates with DNA and facilitates DNA quantity
measurement in the 560-590 nm range of the spectrum using a 585/15 nm optical filter. An
excitation wavelength of 488 nm was used and Cyclin D1 and PCNA expression was detected
with a 533/30 nm optical filter.
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3.2.4

Raman Spectroscopy

125,000 cells were seeded onto calcium fluoride (CaF2) discs (Crystan, UK) for Raman
spectroscopy, treated with thymidine and fixed at the previously described time points. The
cells were fixed with 4% formalin, washed with PBS, then stored in 0.9% physiological saline
at 4°C. A Horiba Jobin Yvon LabRAM HR 800 Dual Microscope Raman Spectroscope with a
785nm laser was used to capture the cell spectra. The LabRAM system is a confocal Raman
spectrometer with a motorised XY sample stage and interchangeable gratings of which the 300
grooves/mm grating was used, giving a dispersion of ~1.5cm-1 per pixel. The confocal pin hole
of the system was set to 100μm and a 16 bit dynamic range charge coupled device (CCD)
detector was used which is Peltier cooled to reduce thermal noise. A 60X /0.9W immersion
objective (LumplanF1 Olympus, Japan) was used to focus on the samples and collect the
backscattered light. Point spectra were taken from the nuclei of the cells. The spectral
acquisition time was 40 seconds per point over two accumulations, and the range over which
the Raman scattered light was detected was 400-1800 cm-1. 74 spectra, one per cell, were
collected overall for each time point from two independent experiments.

Data Analysis

All data analysis was carried out using Matlab (Mathworks, US), with the PLS-Toolbox
(Eigenvector Research Inc.) and in-house algorithms.
Spectral Pre-Processing
The raw Raman spectra were first smoothed using a Savitzky-Golay filter (13 points, 5th order).
Savitzky-Golay filter increases the signal to noise ratio without distorting the signal. The
baseline was then corrected using the rubberband method19, and finally the spectra were vector
normalised (to reduce any variability caused by the fluctuation of excitation power)19.
Principal component analysis (PCA)
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PCA is a form of unsupervised multivariate analysis, which has become a standard processing
technique for Raman Spectral data20. PCA explains the variance in the data by finding
combinations of the original dimensions that describe the largest variance between the data
sets. The output is in the form of a complementary set of score and loading plots termed
principal components (PCs) 20,21.
Linear discriminant analysis (LDA) and Classification Model
LDA is a supervised form of multivariate analysis based on discriminant functions (LDs) which
maximize the variance between groups and minimize the variance within groups. PCA is first
used to reduce the data into PCs which are then used to build an LDA classification model with
leave one out cross validation (LOOCV). In LOOCV all the spectra except for one are used as
a training set and a prediction is made for the left out spectrum. This is repeated so that each
spectrum is left out and predicted once22.

3.3
3.3.1

Results
Cell Cycle Analysis

DNA content was determined by flow cytometry and related to cell cycle phase as shown in
Figure 3.2 (representative measurement), and tabulated in Table 3-1 (average of 6
measurements). At the time of thymidine release, most of the cells were arrested in S phase, 6
h after release, the majority of the cells were in the G2M phase, while 12 h after release most
of the cells were in the G1 phase of the cell cycle.
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(A)

(B)

(C)

Figure 3.2 A representative plot showing cell cycle profile SCC-4 cells; (A) at time of
thymidine release, (B) 6 hours after thymidine release, and (C) 12 hours after release
respectively.

Table 3-1 Mean and standard deviation of cell cycle phases at each time point
Flow cytometry classification (%)
Time point (h) after
thymidine release
0
6
12

3.3.2

S

G2M

G1

75±5
24±12
9±3

12±8
67±7
22±1

9±3
9±4
62±4

Biomarker expression

Cyclin D1 expression was assessed by FITC staining, and 3 measurements were made for each
time point. As can be seen in Figure 3.3, Cyclin D1 expression varied according to the time
point after release, and therefore cell cycle phase, the highest expression being observed in
G2M, followed by G1 and the lowest expression being in the S phase. The expression of PCNA
was assessed by an Alexa Fluor conjugated secondary antibody with 3 measurements made for
each time point. From Figure 3.4 it appears that PCNA expression is very high in S phase
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(~90%) which is reduced to (~60%) in G2M phase and is at its lowest (~10%) in G1 phase of
the cell cycle. Using one way ANOVA, which determines if three independent groups have
significantly different means, PCNA expression was found to be significantly variable across
the different groups (time points). That was not the case with cyclin D1 which was not found
to have variance across the groups. However a two tailed t test revealed that S phase expression
is significantly lower than G2M.

Figure 3.3 Cyclin D1 expression at the different time points, related to cell cycle phases.
Expression is highest at G2M, followed by G1 phase and lowest at the S phase. A two tailed t
test showed that S phase expression is significantly (P<0.002) lower than G2M but not G1.
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Figure 3.4 PCNA expression at different time points, related to cell cycle phases. PCNA
expression is highest in S phase, followed by G2M and lowest in G1. One way ANOVA test
showed that PCNA expression is significantly different (P=0.0006) between the different time
points.
3.3.3

Raman Spectroscopy

From their mean Raman spectra (Figure 3.5); differences between the release time points,
representing the cell cycle phases, were observed. Spectral peak assignments23,24 are tabulated
in Table 3-2. The nucleic acid (600-800 cm-1) and amide 1 regions (1600-1800 cm-1) are more
prominent in the G2M phase, the S phase has more prominent protein and lipid features (around
1400 cm-1), while the G1 phase falls between the S and the G2M phases.
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Table 3-2 Peak assignments of the main Raman vibrational modes found in the spectra and
PC loadings23,24
Wavenumbers (cm-1)

Assignments

621

C-C twist in phenylalanine

783

DNA/RNA ring breathing

1004

Phenylalanine ring breathing

1092

DNA/RNA O-P-O stretching

1336

DNA bases

1440

Fatty acids

1451

Protein (C-H) bending

1575

DNA/RNA ring mode

1673

Amide 1 β pleated sheet

PCA was performed, pairwise, on the processed Raman spectra, which revealed a distinct
separation between the S phase and G1 and G2M phases according to PC1, which explains
47% and 45% of the variance respectively (Figure 3.6). Figure 3.7(A) shows the loading of
PC1 for both S vs G1 and S vs G2M. Scores that are on the positive side of a PC in the scatter
plot reflect the positive side of the loading plot. Similarly, the negative side of the scatter plot
is represented by the negative side of the loading plot25. For both cases, the loading is
remarkably similar, although there are some differences. The loadings indicate that the S phase
is higher in protein content (1451 cm-1, protein C-H bending and 1673 cm-1, Amide 1 vibration)
than G1 and G2M and there is variability in all 3 at 783 cm-1. PC2 does not discriminate
between the S and G phases, but does, at least partially, discriminate the G1 and G2M phases,
for which it explains 8% of the variance. The PC2 loading (Figure 3.7 (B)) shows distinct
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nucleic acid bands on the positive side (783cm-1, 1092 cm-1, 1336 cm-1 and 1576 cm-1),
indicative of higher nucleic acid content in the G2M compared to the G1 phase. The band at
1440 cm-1, on the negative side of PC2, suggests an accumulation of lipids in the G1 phase of
the cell cycle.

Figure 3.5 Mean Raman spectra from SCC-4 cells in each cell cycle phase G1, S, and G2M.
The shading represents the standard deviation.
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(B)

(A)

(C)

Figure 3.6 Two dimensional scatter plots of the first two principal components after PCA was
performed on the spectra from fixed cell nuclei, showing (A) G1 vs S phase (B) S vs G2M and
(C) G1 vs G2M. S phase separated from the other two phases according to PC1, while G1 and
G2M phase separate according to PC2.
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(A)

(B)

Figure 3.7 (A) Loading of PC1 in G2M vs S phase PCA (black) and G1 vs S phase PCA (blue).
S phase is positive in both (B) Loading of PC2 in G2M vs G1 phase PCA. G2M is positive
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3.3.4

Classification Model

To enhance the classification, PCA-LDA with leave one out cross validation was performed
on the spectra. The resulting confusion matrix, shown in Table 3-3, correctly classified 71 out
of 74 spectra (96%) at the 0 hour time point, which is consistent with the predominance of the
S phase, 58 of 74 (78%) at the 6 hour time point, consistent with the predominance of the G2M
phase and 46 out of 74 (62%) spectra at the 12 hour time point, which corresponds to the G1
phase. Corroborating the flow cytometry data (Error! Reference source not found.), the p
ercentage of cells correctly classified in each phase from S through G2M then G1 decreases
corresponding to decreasing synchronicity. Plotting the linear discriminants (Error! R
eference source not found.), a monotonic progression of LD1<LD3<LD2 is apparent in the
negative peaks at 780 cm-1, 1092 cm-1 and 1339 cm-1, all nucleic acid related. The spectral
profile is remarkably similar to PC2 which discriminates the G1 and G2M phases in Error! R
eference source not found. (B). LD1 discriminates between G2M and S phase, LD2
discriminates between G1 and G2M phase and LD3 discriminates G1 and S phase, and the
similarity of the discriminants indicates that nucleic acid content is the primary biochemical
difference between the cell cycle phases.

Table 3-3 A confusion matrix utilising LDA with leave one out cross validation of the principal
component scores showing the Raman predicted percentage of cells at each phase of the cell
cycle.

Raman Classification (%)
Cell Cycle Stage

S

G2M

G1

S

96

0

4

G2M

0

78

22

65

G1

7

31

62

Figure 3.8 Linear Discriminants, LD1 discriminates between G2M and S phase, LD2
discriminates between G1 and G2M phase and LD3 discriminates G1 and S phase.
Spectra of cyclin D1 and PCNA proteins on CaF2 slides were recorded by Raman spectroscopy
(Error! Reference source not found.) to determine whether their varying levels at the d
ifferent stages of the cell cycle could be reflected in the PC and LD loadings. The characteristic
peaks at 812 and 1557 cm-1 of cyclin D1 and at 851 and 1446 cm-1 of PCNA were not, however,
distinct/apparent in either the PC or LD loadings.
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(A)

(B)

Figure 3.9 (A) Spectrum of cyclin D1 (B) Spectrum of PCNA
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3.4

Discussion

The Raman data showed a good separation between S phase and G1 and G2M phases using
PCA. Furthermore, the LDA model showed that the classification was highest at S phase
followed by G2M and G1 phase. This is consistent with the flow cytometry results which
indicated that the cells were well synchronised at the time of arrest (75% S phase), while the
synchronicity was reduced in the G2M (67%) and G1 (61%) phases. An important finding was
that the Raman classification at each phase was higher than its flow cytometry counterpart.
This may be due to the fact that flow cytometry classification is dependent on just the nucleic
acid content, while Raman classification takes into account all the biological molecules within
the nucleus.
Previous cell cycle studies using Raman spectroscopy have used several methods to
synchronise the cells at various phases. Matthews et al. used thymidine to synchronise the cells
at the start of the S phase and nocodazole for synchronisation at the G2/M boundary14, while
Swain et al. used serum starvation to arrest the cells in the G0/G1 boundary, aphidicolin to
synchronise the cells in S phase and nocodazole to synchronise them at the G2/M boundary15.
In this study it was decided to use one cell cycle synchronisation method as opposed to several.
Although this results in less synchronisation in the latter stages, it eliminates any possible
differences due to synchronisation method that can influence the analysis, notably the chemical
signature profiles in the Raman spectra. The differences between G1 and G2M phase were
mainly due to higher lipid (1440cm-1) content in the former and higher nucleic acids (783cm-1,
1092 cm-1, 1336 cm-1 1576 cm-1) in the latter, which is consistent with previous findings that
showed more lipid (700 cm-1, 1438 cm-1) in G1 phase and nucleic acids (669cm-1, 784cm-1,
1100cm-1, 1340cm-1, 1577 cm-1) in G2M phase14. It is important to note that flow cytometry
preparations involve a cell permeabilisation step which could lead to alterations in
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phospholipids. The linear discriminants show a similar progression whereby the nucleic acid
related peaks (780 cm-1, 1092 cm-1 and 1339 cm-1) are highest in G2M followed by G1 phase
and lowest in S phase. This is expected, as the DNA condenses in the G2M phase in preparation
for cell division. The main differences between the S phase and the other two phases, G1 and
G2M, were in the protein content (1451cm-1, 1672cm-1). This may be due to the fact that the
expression of many proteins changes throughout the cell cycle so that the differences could
relate to the changes in specific proteins as opposed to global protein change.
The Raman spectral profiles in the different cell cycle phases show little evidence of
contributions of the biomarkers Cyclin D1 and PCNA. Cyclin D1 levels are moderately higher
in G2M and G1, compared to S phase of the cell cycle. This pattern of cyclin D1 expression
has been reported previously, yet its cause is not well understood26-28. An explanation could be
that cyclin D1 levels are lowest in S phase as the result of proteasomal degradation following
phosphorylation of Thr-286, which occurs specifically in S phase28. On the other hand, PCNA
is synthesised in late G1 and reaches its maximum in S phase9,29. The localization of PCNA
within the nucleus reportedly changes throughout the cell cycle. While its equally distributed
in the nucleus in the G1 and G2 phases, in S phase it aggregates into foci at sites of replication30.
A previous study has shown a Raman signature of PCNA with similar peaks at 483, 675, 849,
922 and 1466 cm-1 31. While no previous studies have examined the Raman spectrum of cyclin
D1, a study by Kumar et al., showing oral tissue with different degrees of cyclin D1 and relating
it back to Raman spectroscopy using a range of 1200-1800 cm-1 found that the tissues with
higher cyclin D1 expression had prominent peaks at 1454 cm-1 and 1560-1583 cm-1 consistent
with the cyclin D1 Raman spectrum measured in his study32. Cyclin D1 and PCNA are proteins
with no specific distinguishing moieties which might give them a distinctive Raman signature,
compared to other proteins. Thus, it is concluded that, in the absence of more refined data-
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mining algorithms, they cannot be used as specific spectroscopic markers for deregulation of
the cell cycle.
In summary this study found that Raman spectroscopy can be used to identify the different
phases of the cell cycle and is perhaps only limited by the efficacy of the cell cycle block.
Furthermore, data on lipid, protein and nucleic acid profiles of the cells can be generated as
opposed to other methods which are limited in the information they provide. However, changes
in particular biomarkers could not be demonstrated with Raman spectroscopy, perhaps due to
the fact that hundreds of proteins are up or down regulated at different points in the cell cycle
which makes it difficult to assess particular ones with an unlabelled method.
The major differences between the phases in the cell cycle are due to variations in nucleic acid
and protein content of the cells, which are similar to the differences between the degrees of
dysplasia. Hence, its ability to discriminate the different phases of the cell cycle gives an
indication of the precision of Raman Spectroscopy in identifying biomolecular changes in the
SCC4 cells which can later be translated to oral tissue samples to identify differences between
pathologies. In the next chapter the protocols for pre-processing Raman spectra of oral FFPP
tissue sections are discussed.
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Chapter 4:

Improved protocols for pre-processing Raman spectra

of formalin fixed paraffin preserved tissue sections
Adapted from ‘Ibrahim O, Maguire A, Meade AD, Flint S, Toner M, Byrne HJ, Lyng FM.
Improved protocols for pre-processing Raman spectra of formalin fixed paraffin preserved
tissue sections. Analytical Methods 2017;9:4709-4717’
OI contribution; experimentation, data analysis and write up.

4.1

Abstract

Although formalin fixed paraffin preserved (FFPP) tissues are a major resource for
retrospective studies of disease progression, their use in vibrational spectroscopy studies has
been undermined by issues of contributions of substrate and paraffin wax which persist in the
spectra and can compromise spectral analysis. Recognising the microcrystalline nature of the
wax in the tissue, which are inhomogeneously oriented with respect to the polarisation of the
Raman source laser, in this study, we have developed a novel method for removing the paraffin
wax contributions to the spectra using matrices of multiple wax spectra. FFPP tissue sections
from the oral mucosca were obtained and, with no further chemical processing, the Raman
spectral analysis of two regions, epithelium and connective tissue were compared. Matrices of
multiple wax spectra were collected from different regions and subtracted from the epithelial
and connective tissue spectra using a least squares analysis with non-negative constraints.
Spectra of multiple cell components such as DNA and RNA were used in fitting the least
squares model to reduce the residual error. The use of a data matrix of multiple wax spectra, as
opposed to a single spectrum, results in a more accurate removal of the wax, hence reducing
its contribution to spectral analysis. In unprocessed FFPP tissue sections, the contribution of
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the glass substrate is seen to be minimised in comparison to chemically dewaxed FFPP tissue
sections. Contributions of the glass substrate were also successfully removed digitally using
the same methodology. The combined results indicate that direct analysis of FFPP tissue
sections is feasible using Raman spectroscopy, avoiding the need for chemical dewaxing.
Additionally, the ability to use glass slides is very important in translation to the clinic.

4.2

Introduction

The standard method used in histopathological tissue processing is formalin fixation followed
by paraffin wax embedding. The tissue is first dehydrated through different grades of ethanol,
then infiltrated with paraffin wax. In this way, the samples are stabilized and can be stored for
years. These formalin fixed paraffin preserved (FFPP) archival tissue libraries can potentially
be a vast resource for retrospective studies of patient history and disease progression.
Vibrational spectroscopy, including Raman scattering and infra-red absorption, has emerged
as a promising candidate for rapid, label free automated screening of tissue pathologies, and
the term spectral histopathology has been coined1. However, paraffin wax poses a difficulty in
vibrational spectroscopic studies of biological tissues, as the wax peaks are prominent and tend
to interfere with either FTIR or Raman spectroscopic analysis2,3. A number of different
approaches to remove the paraffin wax have been tested. Chemical dewaxing agents such as
xylene, hexane, and histoclear were found to reduce but not completely eliminate the presence
of wax and the reduction was seen to be proportional to the time the tissue remained in the
dewaxing agent, resulting in long (up to 18 hours) processing times for optimised protocols3.
The amount of residual wax was also found to be influenced by the choice of substrate and
tissue type. Abnormal tissue, such as metastatic tissue, was found to retain more wax after
dewaxing than normal tissue, while calcium fluoride substrates were seen to retain more wax
than low E slides4. Another disadvantage of chemical dewaxing is that chemical dewaxing
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agents have been shown to modify the tissue composition and therefore spectra5,6. The process
of formalin fixation gives rise to formalin peaks appearing in the spectra at 1041 cm-1 and 1492
cm-1 which can be removed by washing in PBS7. As the molecular structure of paraffin wax is
very similar to that of tissue lipids, the Raman spectral profile of the wax overlaps significantly
with that of the tissue lipids, especially in the region 1000 cm-1 to 1700 cm-1. Because of the
structural similarities, the process of dewaxing can result in modification of the tissue lipidic
content6. Digital wax removal methods such as independent component analysis and nonnegatively constrained least squares analysis (NNLS) have been shown to be a promising
alternative approach. However, these methods tend to introduce artefacts in the spectra due to
over or underestimation of the wax contribution8,9.

Another consideration in the spectral analysis of biological tissue is substrate choice. As the
Raman spectrum of biological samples can be influenced by the optical properties of the
substrate10. For research purposes, spectroscopists prefer to use spectrally neutral substrates
such as calcium fluoride or magnesium fluoride, as they contribute a much lower background
signal compared to glass11. However, they are significantly more expensive and therefore not
a feasible option for routine diagnostic use11,12. Glass is commonly used in histopathological
diagnosis as it is the clinical standard, is inexpensive and allows the processing of hundreds of
samples a day. Its use in Raman spectroscopy, however, is hampered by the fact that glass
exhibits a strong fluorescence emission under 785nm excitation11 , overlaps with the biological
spectra in the fingerprint region12 and its contribution was found to vary with cellular
morphology13. Notably, the glass contribution is significantly lower at 532nm than at the
commonly employed 785nm, making it the wavelength of choice for such clinically oriented
studies. Additionally, a shorter wavelength means greater confocality, higher intensity and a
higher scattering efficacy11. A number of different methodologies have been proposed for
removal of the glass contribution, including iterative subtraction of a polynomial14 or glass
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reference spectrum12 and Kerr et al. have recently performed a comparison of EMCS based
techniques15 to such iterative techniques, suggesting that the former are more effective13.

The aim of this study was to explore improved methodologies of digitally removing the wax
contributions to Raman spectra, for the example of oral tissue sections, thereby retaining the
clinically established tissue processing protocols. The improved methodology is based on a
recognition that the wax in the tissue has a microcrystalline structure. While this is not a
significant factor for macro- or unpolarised micro-spectroscopy, as commonly the case for
FTIR, in the case of Raman microspectroscopy, the microcrystalline domains are randomly
oriented with respect to the polarisation of the source laser and so contribute inhomogeneously
to the response, depending on the sampled spot. This inhomogeneity is accounted for by a
matrix of multiple wax spectra used to digitally process the spectra. The same methodology
was applied to removal of the glass substrate contributions, illustrating that spectroscopic
differentiation of tissue regions can be achieved using Raman spectroscopy, free from
confounding factors of wax and substrate contributions.

4.3
4.3.1

Materials and Methods
Sample preparation

Following ethical approval from the Research Ethics Committee, St James’ Hospital, Dublin,
Ireland, informed consent was obtained from 3 patients who had undergone an oral biopsy
which was diagnosed as benign oral hyperplasia. Tissue blocks from these patients were
obtained, for use in the study. 10µm parallel sections were cut from the FFPP tissue blocks and
mounted on glass slides for Raman spectroscopy.
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For the chemical dewaxing of tissue sections, routine xylene dewaxing was performed, which
involves sequentially immersing the FFPP tissue sections in two baths of xylene, two of ethanol
and one bath of industrial methylated spirits for 5,4,3,2 and 1 minute respectively3. Routine
Hematoxylin and Eosin (H&E) was performed on parallel tissue sections to aid in the
delineation of the different regions in the tissues16. 82 component spectra were available from
an-in house library of spectra of pure biological macromolecules. Matrigel which is a
solubilised basement membrane preparation, was also trialled as a multicomponent reference
biological spectrum, at it has previously been employed as such in background correction
procedures for FTIR 17. Cell components were purchased from Sigma Aldrich. The components
were placed on calcium fluoride disks prior to Raman spectroscopy measurement. All the
components were measured in powder form except for DNA, RNA, cytochrome C, stearic acid,
and collagen which were measured in an aqueous solution. The spectra of the 20 components
(listed in table 1) selected by the Data Analysis procedure are presented in Supplementary Fig
1. For the Matrigel measurements; matrigel (Sigma Aldrich) was placed on a calcium fluoride
disk prior to Raman recording of a matrix of 300 spectral points.

4.3.2

Instrumentation

A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope
was used to record the spectra of the tissue and biochemical components. The microscope has
an automated xyz stage and is coupled to a Peltier cooled CCD detector. A 50mW diode laser
with 532 nm wavelength was used and the grating was set at 600 grooves/mm, while the
confocal hole was set at 100µm. For mapping acquisition, the regions to map were selected
using a 100X objective (MPLAN N Olympus, Japan), which also collected the backscattered
light. The spectra were acquired over two accumulations, totalling 20 seconds per spectrum.
The step size was set at 5µm and the spectral range was 400-1800cm-1. The spectra of the cell
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components were acquired between 10-30 seconds and over 2-3 accumulations depending on
the quality of the signal from the specific sample.

4.3.3

Data Analysis

All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox
(Eigenvector Research Inc.) and in-house algorithms. The spectra were preprocessed by first
smoothing using a Savitsky Golay filter (5th order, 13 points). They were then rubberbanded
to correct the baseline and vector normalised18. Principal component analysis (PCA), an
unsupervised multivariate technique, was used to reduce the dimensionality of the data by
calculating principal components which describe the greatest variance in the dataset19. PCA
was employed to demonstrate the spectral differentiation of regions of epithelium and
connective tissue, and the PC loadings were examined to elucidate the biochemical origin of
the differentiation, as well as contributions of wax or substrate spectral features.

Classical least squares (CLS) fitting is a supervised technique used to estimate the weighted
contributions of a set of input spectra to a sample spectrum. It assumes that any complex
spectrum is the weighted sum of all the base components that contribute to the spectrum as
described in Equation 120.

Equation 4-1

where A represents a sample spectrum, a1, a2 and a3 are component spectra and C1, C2 and
C3 are the weighting coefficients, or concentrations, applied to each component spectrum in
the summation. If one then considers the case of Raman spectroscopy in which a large number
of variables are recorded and not all contributing spectral components are known, then there is
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an error (residual) associated with the estimation which will equate to the difference between
the sample spectrum and the sum of the weighted spectra:

Equation 4-2

Where Ej is the error associated with the intensity of the jth term (or jth wavenumber). The
least squares method aims to minimise the error in fitting the sample spectrum, A. The
minimum error occurs when the differentiation of the sum of squared errors is equal to zero21.
Differentiation of Equation 4-2 with respect to each of the coefficients results in a set of
equations which can be solved using simultaneous equations or matrix mathematics. Non
negatively constrained least squares analysis (NNLS) is a technique similar to that of CLS.
NNLS is used to estimate the weighted contributions of a set of input spectra in a sample
spectrum. However, unlike CLS, NNLS introduces non-negative constraints on the weighting
co-efficients of the input spectra22.

For this study, in lieu of using an average spectrum of wax or glass, matrices acquired from
maps of the wax and glass were used. The wax maps were taken from regions in the samples
with no tissue, while the glass maps were taken from a clean glass slide. The matrices included
about 300 spectral points and were processed in a similar fashion to the sample spectra. To
account for spectral drift from day to day, the wax spectra were interpolated to every quarter
wavenumber. Interpolated spectra were then shifted in both directions in increments of 0.25cm1

to a maximum of +/-1cm-1, and then added to the original matrix of wax. Using an in-house

Matlab algorithm, whereby the Raman spectra of 82 cell components (details in supplementary
table 1) were iteratively tested to represent the tissue for NNLS and the combination of
components associated with the least residual error was selected for use in the wax and glass
subtraction, as listed in Table 4-1 Cell components (Sigma Aldrich) used as inputs for NNLSTable
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4-1. The wax and glass matrices were then subtracted from the original processed spectra. The

steps are summarised in Figure 4.1 The NNLS procedure weighted the contributions of each in
an unsupervised fashion. However, the intention was to optimise the wax removal protocol,
rather than to model the tissue analytically, based on the relative contributions of the specific
components. Least Squares analysis, either supervised or unsupervised, has previously been
used in a number of studies as a spectral analysis protocol23,24. CLS was used to determine the
wax contribution to the first principal component of the unprocessed, chemically processed and
digitally processed tissue.

Table 4-1 Cell components (Sigma Aldrich) used as inputs for NNLS

Cell Components
Proteins

Lipids

Nucleic
acids

Nucleic bases

Glycosaminoglycans

Other

Actin

Stearic acid

RNA

Thymidine

Heparin

Taurin

Collagen

P-Choline

DNA

Uracil

Hyauloronic acid

Cytochrome C

P-Ethanolamine

Guanine

L-Histidine
L-Serine
L-Theronine
Peroxidase
Ubiquitin
Apo E2
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Figure 4.1 Summary of the processing steps for the Raman spectra.

4.4

Results

Figure 4.2 shows a H&E stained FFPP tissue section, highlighting the epithelium and
connective tissue regions. Raman maps were taken of the epithelium and connective tissue
regions in the unprocessed FFPP tissues, the mean and standard deviation of which can be seen
in Fig 3. Initially, PCA was performed on the tissue spectra without removing the glass and
wax contributions (Figure 4.4 (A)). The first principal component (PC1), which explained 59%
of the variance, does not differentiate the two tissue types, and is dominated by wax peaks at
1063, 1134, 1172, 1296, 1419, 1441 and 1464 cm-1 (Figure 4.4 (B)), which account for 38% of
the loading. The broad streaking of the datasets indicates a significant variability of these
contributions across both datasets. The second principal component (PC2), according to which
the epithelium and connective tissue spectra are differentiated, explained 5% of the variance
(Fig 4 (C)). The datasets are more tightly clustered with respect to PC2 and the loading has
strong peaks at 815, 857, 875, 920 and 1245 cm-1. These relate to collagen type 1 which,
together with fibroblast cells, is the main component of the connective tissue25,26. The loading
of PC2 also contains contributions from wax, but notably, some of them contribute negatively
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to the loading (1419, 1438 cm-1), while some contribute positively (1136, 1296 cm-1) indicating
that the spectrum of the wax itself is not uniform across the tissue section. Glass peaks do not
appear in the first or second principal component (Figure 4.4 (C)) indicating that the glass
contribution to the spectra is not significant. Thus, the differentiation, using Raman
microspectroscopy, of the two clearly biochemically distinct regions of tissue is based on their
wax content, rather than their biochemical composition, which does not bode well for the
potential to distinguish differing pathologies in the same tissue regions.

Figure 4.2 Bright field image of H&E stained FFPP tissue showing the epithelium and
connective tissue regions.
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Figure 4.3 Mean Raman spectra of epithelium and connective tissue in the unprocessed tissue
sample. Shading denotes the standard deviation.

The chemically dewaxed tissue sections were visually different from the unprocessed tissue
sections, as they appeared whiter, indicating increased scatter which may be due to increased
porosity as the wax and some of the lipidic content is removed in the dehydration process.
Raman analysis of the chemically dewaxed tissue sections showed that, although the wax peaks
at 1063cm-1 1134cm-1, 1172cm-1, 1296cm-1, 1419cm-1, 1441cm-1 and 1464cm-1 were reduced
in comparison to the unprocessed tissue, they were not eliminated. Furthermore, the glass
contribution in the chemically processed FFPP tissues was higher compared to the unprocessed
tissues (Figure 4.5 (A)). Acquiring the spectra for connective tissue was problematic, as many
of the spectra were saturated. This may be due to the increased scattering of the tissue after
dewaxing, a phenomenon which can be reduced in a water immersion measurement protocol27.
The epithelium appears to retain more wax and has a higher glass contribution in comparison
to the connective tissue (Figure 4.5 (B)).
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(A)

(B)

(C)

Figure 4.4 (A) PCA scatter plot of unprocessed epithelium and connective tissue shows a clear
separation on the second principal component with even distribution along the first principal
component. (B) The first principal component is dominated by wax spectral peaks. (C) The
second principal component is mainly collagen type 1 associated peaks on the positive side,
relating to connective tissue, and protein associated peaks on the negative side, relating to
epithelium.
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(A)

(B)

Figure 4.5 (A) Mean Raman spectra of epithelium in the unprocessed (black) and chemically
dewaxed (blue) tissue sample and mean Raman spectrum of glass (red). Compared to the
unprocessed epithelial tissue, the chemically dewaxed tissue has less wax contribution and
more glass. (B) Mean Raman spectra of epithelium and connective tissue in chemically
dewaxed FFPP tissue section. Shading denotes the standard deviation. The black arrows
highlight peaks from wax. The epithelium has more wax and glass contribution than the
connective tissue.

PCA of the epithelium and connective tissue showed that the collagen and protein related peaks
815, 857, 875, 920 and 1245 cm-1 had been promoted to the first principal component which
explains 75% of the variance (Figure 4.6). However, although the contribution has been
significantly reduced, there was still 32% wax contribution in the loading of the first PC, which
positively discriminates the epithelium. Additionally, the two broad peaks of glass can be
discerned in the loading of the first PC. This is to be expected, as there was a higher contribution
of wax and glass in the epithelium.
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(A)

(B)

Figure 4.6 (A) PCA scatter plot of chemically dewaxed epithelium and connective tissue shows
a separation on the first principal component. (B) On the positive side of the first principal
component, collagen type 1 related peaks (red arrows) can be distinguished. While some wax
(black arrows) and protein peaks can be distinguished on the negative side.

The spectral dataset for the FFPP sections, in which the wax contribution was removed digitally
(using NNLS), were analysed. Wax removal with a single wax spectrum was found to be
insufficient, as most of the wax peaks were either over or underestimated. PCA of the matrix
of wax spectra clearly illustrates the variability of the spectral signature of the nominally single
chemical constituent, as shown in the scatterplot in Figure 4.7 (A). Notably, rather than
exhibiting a widely scattered cluster centred about zero, the curved distribution is suggestive
of an interdependence of PC1 (Figure 4.7 (B)) and PC2 (Figure 4.7 (C)), each indicating the
degree of variability of the wax spectrum on a microscopic level. Although, macroscopically,
paraffin is an amorphous wax, on the microscopic scale of the Raman laser spot, it presents a
microcrystalline structure28, and, as the laser is polarised, the registered spectrum is
significantly variable, depending on the relative orientation of the laser polarisation and the
microcrystalline structures. A single or averaged spectrum does not represent the specific
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spectral contributions at any point on the tissue, and therefore a subtraction protocol based on
such results in incomplete removal of the spectral contributions of the paraffin.

(A)

(C)

(B)

(D)

Figure 4.7 (A) PCA scatter plot of Wax matrix. (B) The first Principal component which
explains 85% of the variance (C) The second principal component (D) Comparison of digital
wax removal in epithelial tissue using a matrix of wax vs a single wax spectrum. Note, although
the NNLS protocol constrains the weightings co-efficients to be non-negative, the component
spectra can have negative contributions.
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Rather than averaging; a matrix of 300 individual spectra retains the intrinsic variability of the
wax contributions, each of which is individually weighted in NNLS subtraction. The protocol
resulted in much more efficient wax removal, as shown in Figure 4.7 (D). The resultant spectra
of epithelium and connective tissue appear more uniform and have reduced wax contribution
(Figure 4.8). This was also reflected in the PCA of epithelium and connective tissue, as the
wax contribution to the loading of the first PC, which accounted for 90% of the variance, was
reduced to 10%. The collagen and protein related peaks at 815 cm-1, 857, 875, 920 and 1245
cm-1 can be clearly distinguished in the first PC. Additionally, the spectra were tightly grouped
according to PC1 in the PCA scatter plot, suggesting reduced variability within the groups and
greater uniformity (Figure 4.9), although considerable point to point sample variability is
evident by the spread according to PC2, particularly for the case of the connective tissue.

Figure 4.8 Mean Raman spectra of epithelial and connective tissue after digital wax removal.
Shading denotes the standard deviation.

89

(A)

(B)

Figure 4.9 (A) PCA scatter plot of epithelium and connective tissue after digital wax removal
using the cell components as a model. Epithelium is made up of tightly packed cells whereas
connective tissue contains collagen fibrils, fibroblasts, blood vessels and oil ducts leading to a
greater variability in the latter according to PC2 (B) First PC after digital wax removal. Wax
contribution, black arrows, is reduced. The red arrows refer to 815, 857, 875, 920 and 1245
cm-1 which are collagen related peaks.

For the glass removal, NNLS was also used. In a similar fashion to the wax removal, the glass
contribution was reduced without affecting the integrity of the spectra (Figure 4.10). However,
in contrast to the case of wax, where the use of a matrix conferred a marked improvement,
there was no real difference between the use of a glass matrix or single spectrum in glass
removal, indicating that the glass spectrum is more spatially homogenous (Figure 4.10 (B)).
This is confirmed by the spectra being equally dispersed around the PC1 and PC2 axes, and
showing no systematic variability (Figure 4.10 (C)).
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(A)

(B)

(C)

Figure 4.10 (A) Mean Raman spectra of chemically dewaxed epithelial tissue before and after
digital glass removal. (B) Mean Raman spectra of chemically dewaxed epithelial tissue with
glass removal using a matrix and a single spectrum. (C) PCA scatter plot of the glass matrix.

4.5

Conclusions

One of the advantages of using vibrational spectroscopy techniques, such as Raman
spectroscopy, to analyse biological tissues is that they require minimal sample preparation. In
this study, chemical dewaxing, which increases the processing time and alters the composition
of the tissue, has been substituted by an improved protocol for digital dewaxing. The demand
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for an improved protocol for spectroscopic analysis of the FFPP tissue sections had been
previously highlighted29. As demonstrated in Figure 4.4 the contributions from the wax
significantly influence spectral analysis, which establishes the importance of subtracting it.
From the results, it is clear that this method of digital removal greatly reduces the spectral
contribution of wax, as the variance from the wax contribution to the first principal component
is reduced from 38% and 32% in unprocessed and chemically processed samples respectively
to 10% in the digitally dewaxed samples. Furthermore, the chemically dewaxed FFPP tissue
samples had more glass background in the epithelium and more scattering background in the
connective tissue compared to their unprocessed counterparts. This is most likely due to
refractive index matching between the wax and glass resulting in reduced scattering of the
incident light and Raman bands themselves in the unprocessed samples. The superiority of
digital versus chemical wax removal has also previously been reported in FTIR spectroscopy,
whereby modified extended multiplicative signal correction (EMSC) was used for the wax
removal30. Because of the variability between, and within, different types of tissue, while using
a single mean cellular spectrum as a model or reference, such as has been previously reported
for EMSC, is effective for cytology samples, it underestimates the complexity of
histopathological tissue samples which can include epithelium and connective tissue, as well
as different types of pathology13. Similarly, both EMSC and Independent component analysis
rely on a definitive model of wax (such as a three source model8) which does not take into
account the variability of the paraffin wax spectrum, accentuated in Raman spectroscopy due
the polarisation dependence of commonly employed instruments. The use of multiple spectral
components for the reference and wax contributions provides flexibility to account for the
observed point to point variations of both.
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This study is the first to utilize cell components and a wax matrix in the digital removal
of wax from FFPP tissue sections. As the wax spectrum is composed of a number of
peaks, and the ratio between these peaks is variable from one wax spectrum to another;
using a matrix of wax captures this variability which therefore reduces the residual error
in the NNLS model and results in improved estimated spectra. Paraffin wax is made up
of linear hydrocarbon molecules which can form crystallites on a microscopic scale 21.
As these can be randomly oriented with respect to the laser polarisation, their
contribution to the Raman spectrum of the tissue can be highly spatially variable.
Polarisation dependent studies are frequently employed to study the orientation of, for
example, molecules in liquid crystals31

and have been employed to study the

constituents of bone32. A study conducted, exploiting the polarisation dependence in
biological tissues, has shown that in probing the deeper layers of the tissues the
backscattered light has a greater chance of being depolarised by diffusion compared to
the more superficial layers33.
In contrast, glass has two broad peaks in the fingerprint region. Almost no difference
was observed in the subtraction of glass using a single glass spectrum and using a glass
matrix. However, this may be due to the fact that the glass contribution was not high in
these samples and more or less uniform across the sample, so the matrix subtraction may
be more effective in samples which show greater variability.
The cell components were selected from a pool of 82 components based on their fit of
the NNLS model and, similar to the wax matrix, they confer a significant improvement
on the wax subtraction. Choosing whether to use a single, commercially available
component such as Matrigel or collections of biomolecules as representation of tissue
constituents can depend on the application and the expected variability of the samples
under investigation. For the application demonstrated here, the cell components gave
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superior performance in the removal of wax contributions to the spectra as the residual
error was reduced from 18% when Matrigel was used in the NNLS correction to 8%
when the cell components were used. A further improvement in the efficacy of removal
could potentially be achieved by a more representative choice of cellular constituent
spectra, targeted at specific tissue types.
By interpolating the wax spectra to every quarter wavenumber and shifting in both
directions, the small spectral drifts from day to day calibration were accounted for
resulting in a more accurate wax removal.
For a diagnostic technique to be translatable into routine clinical use it has to be
affordable, and reliable. Effective digital subtraction of glass contribution from spectra
means that glass could be used for FFPP or cytological samples, making vibrational
spectroscopy techniques more affordable. The digital subtraction of wax using a matrix,
decreases the processing time and involves less modification of the samples resulting in
more reliable results.
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Chapter 5:

Raman spectroscopy for the identification of dysplastic

changes in FFPP oral tissues (an intra-patient study)

5.1

Introduction

OSCC is commonly preceded by a range of cell and tissue alterations, described in Table 5-2,
which are similar to the changes seen in carcinoma, but restricted to the surface epithelium.
These changes, termed dysplasia, have been classified by the World Health Organisation
(WHO), according to their severity, as1;
Table 5-1 WHO classification of oral dysplasia
Degree of dysplasia

Features

Mild dysplasia

Architectural (tissue) changes limited to the
lower third of the epithelium with minimum
cellular atypia

Moderate dysplasia

Architectural changes extend to the middle
third of the epithelium with cellular atypia

Severe dysplasia

Architectural changes that cover more than
two thirds of the epithelium with marked
cellular atypia

Carcinoma in situ

Architectural changes that extend to the full
thickness of the epithelium with marked
cellular atypia. The difference between
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carcinoma in situ and OSCC is the presence
of invasion in OSCC.

The WHO classification system is the most widely used, although other classification systems
have been devised, such as the one by Smith and Pindborg which classifies dysplasia as; none,
present, or marked2. The oral intraepithelial neoplasia (OIN) System classifies dysplasia as
none, OIN 1 and 2 which correspond to mild and moderate dysplasia respectively and OIN 3
which corresponds to severe and/or carcinoma in situ3.
Table 5-2 Cellular and tissue features of oral epithelial dysplasia4
Cellular changes

Tissue changes

Increased nuclear/cytoplasmic ratio

Loss of polarity of the basal cells

Increased number and size of nucleoli

Drop shaped rete ridges

Cellular pleomorphism (variations in size and Disordered maturation from basal to squamous
shape)

cells

Nuclear pleomorphism

Increased cellular density

Increased number of mitotic figures

Basal cell hyperplasia

Abnormal mitotic figures (abnormal in shape Dyskeratosis (premature keratinization and
or location)

keratin pearls deep in epithelium)

Hyperchromatic nuclei

Loss of intercellular adherence
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However, as mentioned in section 1.3.5 , histopathological classification is prone to inter- and
intra- observer errors and the progression of dysplasia is not a linear process, so the degree of
dysplasia is not necessarily a predictor for malignant transformation5,6. A previous ex-vivo
study used Raman spectroscopy to classify oral lesions as normal, benign, premalignant and
OSCC7. An in-vivo study was able to discriminate between normal, premalignant and
malignant oral mucosa with an accuracy of 85%8. Another in-vivo study discriminating
between premalignant lesions, normal mucosa and the mucosa of habitual tobacco users could
classify the premalignant lesions with an accuracy of 80% using LOOCV and only 50% using
an independent test set9. However, none of these studies took into account the presence or
degree of dysplasia in the premalignant lesions.
The aim of the current study is to use Raman spectroscopy to discriminate between mild,
moderate and severe dysplasia in FFPP tissues from biopsies of 4 patients who had undergone
multiple biopsies over time. Studying the range and progression of dysplasia in the same
patients reduces the differences due to genetic variability and can help understand the
progression of the disease. Two methods were trailed for classification purposes, PCA-LDA
which has been described in section 3.3.5 and partial least squares regression discriminate
analysis (PLSDA). Data for progression in one patient is shown below.

5.2
5.2.1

Methodology
Sample preparation

Ethical approval from the Research Ethics Committee, St James’ Hospital, Dublin, Ireland, and
informed consent was obtained from a patient who had undergone multiple oral biopsies. 10µm
sections were cut from the FFPP biopsies and mounted on glass slides. On the slide, the regions
with the different pathologies (such as mild or moderate dysplasia) were marked by the
pathologist.
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5.2.2

Instrumentation

A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope
with a 532 nm wavelength laser was used. The properties of the spectroscope and mapping
details were described in chapter 4, section 4.3.3 . Two maps were taken for each pathology,
one of epithelium and one of connective tissue. Each consisted of 200 spectral points taken at
10µm intervals.
5.2.3

Data Analysis

All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox
(Eigenvector Research Inc.) and in-house algorithms. Two quality control steps were
employed. In the first, before processing, spectra with excess scatter/background were
eliminated by setting a maximum intensity. Processing involved smoothing with a Savitsky
Golay filter (5th order, 13 points) then correcting the baseline with a rubberband function, and
finally vector normalisation. The second quality control step involved removing the spectra
with excess wax and low biological content. This was achieved using k-means clustering which
is used to partition data into groups such that variation is minimized within groups but
maximized between groups. Most of the current versions are based on the algorithm developed
by Hartigan and Wong in 197910. It assigns data points to their closest centre points which are
updated (changed) with each iteration until optimal convergence is met10. The next step was
subtracting the wax and glass backgrounds; which was done using the NNLS method described
in section4.3.3 . Figure 5.1illustrates the spectral preprocessing steps.
PCA of the data was performed to elucidate whether there is discrimination between the
different pathologies and the basis for that discrimination.
PCA-LDA: Information from the first 10 principal components was used to build an LDA
model with LOOCV.
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PLSDA: mean centering (dividing all the variables by the mean) was performed on the
processed spectra before PLSDA modelling. This serves to adjust for the variance between
large and small unit variables, leaving only the relevant variance (that between the samples)
for analysis. Partial least squares regression (PLSR) is a generalization of multiple linear
regression (MLR) in which a set of dependent variables y is regressed against independent
predictor variables X11. PLSDA is a supervised form of multivariate analysis which works as
a linear classifier that aims to separate the data into groups using a hyperplane, similar to LDA;
it aims to maximise the variance between groups and minimise the variance within groups. It
is based on PLSR. Whereas, in classic PLSR, y is a matrix of continuous variables, in PLSDA
it is categorical and used to assign the observations into classes. The loadings of the
discriminate hyperplanes or latent variables (LV)s can be plotted to give more information on
the source of the variance12. The data was divided into y classes from 1 to 3, corresponding to
mild, moderate and severe dysplasia.
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(A)

(C)

(B)

(D)

Figure 5.1 Spectral processing steps (A) Raw spectra. (B) Spectra after first quality control
step, smoothing, baseline correction and normalization. (C) Spectra after k-means grouping;
the spectra in red have high wax and low biological content while those in blue have higher
biological content and less wax. (D) Spectra after glass and wax subtraction.
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Table 5-3 Raman peak assignments, adapted from Movasaghi et al.13.
Wavenumber (cm-1)
484-90
599/600
666
752
782
811/12
814
838
855
919
934/935
937/8
1001/2
1030-34
1128/9
1131
1237
1245-8
1265
1278
1285
1315-17
1333
1336
1368
1373
1437
1441
1449/50
1460
1554
1572-78
1650
1652-55
1666-8
1674
1700-50

Assignment
Glycogen
Nucleotide conformation
G,T (ring breathing modes in DNA bases)
Symmetric breathing mode of tryptophan
DNA
RNA O-P-O stretch
C-C stretching (collagen assignment)
Deformative vibrations of amine groups
Ring breathing in tyrosine/C-C stretching in proline
C-C stretch of Proline ring/ glucose lactic acid C-C, proline
ring (collagen assignment)
Protein/C-C backbone (collagen assignment)
Proline, hydroxyproline (C-C) skeletal of collagen backbone
Phenylalanine ring breathing
Phenylalanine of collagen
Skeletal C-C stretch in lipids
Fatty acid
Amide III
Amide III of collagen
Amide III
Proteins including collagen I
Differences in collagen
Guanine
Guanine
Polynucleotide chain (DNA purine bases)
Guanine TRP protein, porphrin, lipids
T,A,G (ring breathing modes of the DNA/RNA bases)
CH2 deformation (lipid)
Wax
C-H vibration lipids
CH2/CH3 deformation in Lipids
Amide II
Guanine adenine
Amide I
Lipid C=C (lipids) / Amide I
Protein / collagen
C=C stretch in cholesterol
Amino acids aspartic and glutamic acid
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5.3

Results

According to their mean spectra, mild, moderate and severe dysplasia appear similar (Figure
5.2), which is why multivariate methods are employed to better observe the differences.

Figure 5.2 Mean Raman spectra of mild, moderate and severely dysplastic epithelial tissue.
Shading denotes standard deviation.
PCA showed a good discrimination between mild and severe dysplasia according to PC1
(Figure 5.3 (A) (B)). Negative peaks in PC1 relating to the mild dysplasia are attributed to lipid
(1128) and protein (935, 1652 cm-1, 1462 cm-1) contributions (Figure 5.3 (B)). On the positive
side of the PC loading, relating to severe dysplasia, the most prominent peaks are attributed to
nucleic acids (666, 1375 cm-1) and protein (1555, 1709 cm-1). Similar results were obtained in
discriminating moderate and severe dysplasia (Figure 5.3 (C) (D)). Negative peaks in PC1 at
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666, 1375 cm-1, 1555, and 1709 cm-1 relate to the severely dysplastic epithelium. Positive peaks
at 715, 934, 1129, 1296, 1445 and 1655 cm-1 relate to the moderately dysplastic epithelium.
The peak at 1296 cm-1 is a paraffin wax feature whose variance, although reduced, is not
eliminated. No discrimination was found between mild and moderate dysplasia in PCA (Figure
5.3 (E) (F)). This suggests that lipids and proteins are more prominent in the mildly and
moderately dysplastic tissue, while nucleic acids and proteins are more prominent in the
severely dysplastic tissue.
According to their mean spectra, differences between mild / moderate and severe connective
tissue are observable, especially in the regions 800-1000 cm-1 and 1200-1400 cm-1 (Figure 5.4).

106

(A)

(B)

(C)

(D)

(E)

(F)

Figure 5.3 Results of PCA in epithelium (A) PCA scatter plot of mild vs severe dysplasia (B)
Loading of PC1 which explains 42% of the variance (C) PCA scatter plot of moderate vs severe
dysplasia (D) PC1 which explains 42% of the variance (E) PCA scatter plot of mild vs moderate
dysplasia (F) PC1 which explains 31% of the variance.
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Figure 5.4 Mean Raman spectra of Mild, Moderate and severely dysplastic connective tissue.
Shading denotes standard deviation.

A good discrimination between mild and severly dysplastic connective tissue was
demonstrated with PCA (Figure 5.5 (A)). The negative side of PC1, which relates to the mildy
dysplastic connective tissue, was dominated by collagen related peaks at (814, 856, 939, 1034,
1243 and 1667 cm-1), while, the positive side, relating to severe dysplasia, was dominated by
nucleic acid contributions (1314, 1335 and 1365 cm-1) (Figure 5.5 (B)). Similar results were
found on discriminating moderate and severe dysplasia (Figure 5.5 (C)(D)). PCA showed no
discrimination between the mild and moderately dysplastic connective tissue.
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(A)

(B)

(C)

(D)

(E)

(F)

Figure 5.5 Results of PCA in connective tissue (A) PCA scatter plot of mild vs severe dysplasia
(B) Loading of PC1 which explains 75% of the variance (C) PCA scatter plot of moderate vs
severe dysplasia (D) PC1 which explains 73% of the variance (E) PCA scatter plot of mild vs
moderate dysplasia (F) PC1 which explains 41% of the variance.
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Table 5-4 summarises the sensitivity and specificity values obtained from the PCA-LDA
classification with LOOCV. For both epithelium and connective tissue, severe dysplasia has
the highest accuracy of discrimination in Raman followed by mild then moderate dysplasia.
The discrimination in epithelium is better overall than that in connective tissue. Table 5-4
displays the sensitivity and specificity values obtained from the PLSDA classification with
LOOCV. It follows the same trend as the PCA-LDA classification although the sensitivity and
specificity values are higher overall.

Table 5-4 Sensitivity and specificity values obtained for the PCA-LDA classification model

Severe
Moderate
Mild

Epithelium
Sensitivity (%)
Specificity (%)
100
99
88
95
92
95

Connective Tissue
Sensitivity (%) Specificity (%)
98
98
63
89
79
82

Table 5-5 Sensitivity and specificity values obtained for the PLSDA classification model

Severe
Moderate
Mild

5.4

Epithelium
Sensitivity (%)
Specificity (%)
100
99
96
95
97
95

Connective Tissue
Sensitivity (%) Specificity (%)
98
98
78
84
91
71

Discussion

Discriminating between low grade dysplasia (mild and moderate) and high grade (severe and
CIS) is important, as it determines both the management course and patient prognosis. High
grade dysplasia have a higher risk of transformation and thus are treated more radically, while
low grade dysplasia, depending on location and extent, may just be monitored. In this study, of
interest are the changes taking place in epithelium and connective tissue during mild, moderate
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and severe dysplasia, as identified by Raman spectroscopy. The choice to study each part of
the tissue (epithelium and connective tissue) independently was made in order to better
understand/identify the changes taking place in each. While it was expected to find
discrimination between severe, mild and moderate in the epithelium, as the epithelial cells are
undergoing morphological and biochemical changes, significant differences in connective
tissue between the pathologies was not expected.
In the epithelium, the most prominent feature in the severely dysplastic epithelium was an
increase in the nucleic acid related peak at 1375 cm-1 and a reduction in the peaks at 1128 and
1462 cm-1, which relate to skeletal C-C stretch and CH2/CH3 deformation in lipids,
respectively, in comparison to the mild and moderately dysplastic tissue. This has previously
been reported in relation to OSCC14 and can be explained by the higher replication rate and the
relative increase in nuclear to cytoplasmic ratio in the more severe dysplasia. The spectral
profile of the tissues in relation to proteins, however, is more complex, as peaks at 934 and
1650 cm-1, which relate to protein C-C backbone and Amide I/lipids respectively, were higher
in the mild and moderately dysplastic epithelium compared to severely dysplastic. Similar
results were found by Cals et al. when comparing OSCC to surrounding normal squamous
epithelium, as these peaks were higher in the normal epithelium15. On the other hand, severely
dysplastic epithelium had higher peaks at 752 cm-1 (tryptophan) and 1555 cm-1 (Amide II).
This suggests fewer proteins in the α helix conformation16 in severely dysplastic epithelium,
which may be due to disordered protein structure resulting from weakened bonds or a change
in the amino acid microenvironment17. Increased Amide II may be due to upregulation of some
proteins in the dysplastic progression, while increased tryptophan, an important amino acid in
metabolic activities, has been reported previously in malignant cells17-19.
The most significant change in connective tissue is in the collagen related bands (Table 5-3),
which is reduced in the more severely dysplastic tissue. This has previously been described in
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gastric dysplasia and ascribed to changes in matrix metalloproteinases which cleave collagen20.
It may also be relative to an increase in cellularity in the severely dysplastic tissue. Mild and
moderately dysplastic tissue did not show a good discrimination on PCA which is not very
surprising as the categories are sometimes confused by the pathologists especially in borderline
cases. More supervised classifiers, in this case LDA, and PLSDA were required to find the
variance.
Overall, these results suggest that Raman spectroscopy can identify differences in mild,
moderate, and severely dysplastic tissue which relate to relative changes in nucleic acid, lipid
and protein content. By analysing these changes in a single patient, any differences due to
genetic variability have been reduced. In Figure 5.6 the loading of LV-1 from the PLSDA of
epithelium in each of the 4 patients (A-D) shows the progression from mild through moderate
and severe. From the loadings it is apparent that while A and B have similar signatures, C and
D are different.

(A)

(B)

(C)

(D)

Figure 5.6 Loading of LV-1 from the PLSDA model for 4 patients A-D
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This suggests that there may be some interpatient variability when it comes to progression from
mild, through moderate to severe dysplasia. Hence doing an interpatient study, where the
patients are grouped according to class (pathology) can be more informative, this is presented
in chapter 6.
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Chapter 6:

Raman spectroscopy for the identification of dysplastic

and malignant FFPP oral tissues (inter-patient study).

6.1

Introduction

In this study, the work from the previous chapter is expanded on by studying the differences
between benign, mild, moderate, severely dysplastic and OSCC FFPP tissue in a cohort of
patients. The archival FFPP patient samples were obtained from St James’ Hospital, Dublin.
The benign category was made up of benign lesions, such as fibroepithelial polyp, squamous
papilloma and benign hyperplasia. Fibroepithelial polyps are reactive lesions with an
underlying aetiology of trauma or irritation. They are characterised by a small growth which
can occur anywhere in the oral cavity, although they are most commonly found in the gingiva,
tongue and lip1. Similarly, squamous papillomas are exophytic asymptomatic growths,
although their pathogenesis is assumed to be viral, as they have been tentatively linked to HPV
types 6 and 112. Hyperplastic lesions are benign lesions that are keratotic but show no cellular
atypia. Raman spectroscopic measurements were taken of the tissues and partial least squares
regression discriminate analysis (PLSDA) was used to classify the tissue samples into classes
of benign, mild, moderate, severe dysplasia and OSCC. PLSDA was chosen over other
multivariate techniques, such as PCA-LDA and support vector machine (SVM), for a number
of reasons. Firstly, the results of chapter 5 revealed that it was better at discriminating between
mild, moderate and severe oral dysplasia. Furthermore, unlike LDA, it can analyse data with
numerous x variables, and it works well with data that is noisy or has highly collinear x
variables3. A study comparing PCA-LDA and PLSDA models for colorectal cancer diagnosis
found that PLSDA could discriminate between normal and cancerous tissue with a higher
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accuracy than PCA-LDA4. PLSDA is not without its limitations, however, as it can tend to
overfit the model, meaning it can classify training data well but not new data5. This can be
overcome by using a validation data set or, as in this case where there are a small number of
samples, by using cross validation.

6.2
6.2.1

Methodology
Sample Preparation

Archival oral FFPP tissues for each cohort were obtained following ethical approval from St
James’ Hospital Ethics Committee and informed written consent from patients. In total, 57
patients were included, from which 72 pathologies were identified. 17 were benign lesions, 20
mildly dysplastic, 20 moderately dysplastic, 10 severely dysplastic and 5 invasive SCC. The
H&E stained sections from the different pathologies were examined by a consultant oral and
maxillofacial pathologist in St James’ Hospital, who then edited the images to mark the areas
of pathology (Figure 6.1). The FFPP tissue blocks and corresponding images were then taken
to the RESC laboratory where10µm sections were cut from the FFPP tissues and mounted on
glass slides. One of the sections from each sample was dewaxed, stained with haematoxylin
and eosin, and a parallel unstained section (which was not dewaxed) was used for Raman
spectroscopy measurement.
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mod

Severe
dysplasia

mild

Figure 6.1 Representative H&E images showing the regions of dysplasia marked by the
pathologist.

6.2.2

Instrumentation

A confocal Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope
with a 532 nm laser was used. The instrument and mapping properties are described in section
4.3.2. For every pathology section, 200 spectral points were taken from epithelium and the
same from connective tissue at 10 µm intervals.
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6.2.3

Data Analysis

All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox
(Eigenvector Research Inc.) and in-house algorithms. The spectral pre-processing steps are
described in section 5.2.3.
PLSDA with leave one patient out cross validation (LOPOCV) was used to build the classifier.
LOPOCV is similar to LOOCV except, in this instance, in place of leaving one spectrum out,
one patient is left out so that all the spectra of the patient are left out and predicted.
Receiver operating characteristic (ROC) curves were graphed for each class. ROCs are a plot
of the true positive rate (sensitivity) against the false positive rate (1-specificity) over a
continuous range (from 0 to 1) of cut-points of a classifier. Each point on the ROC curve
represents a sensitivity/specificity pair corresponding to a particular decision threshold.
Accuracy is measured by the area under the ROC curve (AUC), so that, the closer the curve
tends to the left and top borders, the more accurate the classifier. Conversely, the closer the
curve is to the diagonal (baseline), the higher the misclassification rate and the lower the
accuracy6.The baseline is at 0.5, while a perfect classifier would have an AUC of 1.In general,
an AUC of 0.5 is considered to have no discrimination, while 0.7 to 0.8 is considered
acceptable. 0.8 to 0.9 is considered excellent while over 0.9 is considered outstanding7. A
schematic of an ROC curve is shown in Figure 6.2.

119

Sensitivity (true positive rate)

Increasing accuracy

1-specificity (false positive rate)

Figure 6.2 Schematic of an ROC curve. Sensitivity is plot on the y axis and 1-specificity on the
x axis. Accuracy is increased as the curve goes towards the left and top borders (increasing the
AUC) and decreases as the curve goes inwards towards the baseline (decreasing the AUC).

6.3

6.3.1

Results

Epithelial tissue

The mean spectra of the benign, mild, moderate and malignant epithelial tissues all appear
similar (Figure 6.3), demonstrating the need for more sophisticated multivariate analytical
techniques, such as PLSDA, to differentiate the tissue pathologies based on the spectral
signatures of their differing biochemical constituents.
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Figure 6.3 Mean Raman spectra of benign, mild, moderate and severely dysplastic epithelial
tissue. The spectra have been offset for clarity and shading denotes standard deviation.
The results of the PLSDA classification do not show a very good discrimination across the
groups (Table 6-1). The estimated ROC curves are based on predicted class for each spectrum.
Sensitivity is calculated from the fraction of in class spectra while the specificity is calculated
from the fraction not in class for a given threshold. The cross validated ROC curves follow the
same method except the class predicted when the spectra are left out during cross validation is
used. From the ROC curves (Figure 6.4) it appears that the classifier has the highest accuracy
for SCC (AUC=0.71) and lowest for mildly dysplastic epithelium (AUC=0.46).

121

Table 6-1 Sensitivity and specificity values obtained from PLSDA classification with
LOPOCV of epithelial tissue.
Benign

Mild

Moderate

Severe

OSCC

Sensitivity (%)

74

67

39

69

65

Specificity (%)

49

38

86

57

76

To assess whether it affects the classification, different combinations of the pathologies were
assessed. Combining the severely dysplastic and SCC group did not have much effect on the
overall model (Table 6-2). However, combining the mild and moderate groups leads to an
improved classification in the other groups (benign, severe and SCC), but a low classification
in the mild/moderate group (Table 6-3).
Table 6-2 PLSDA classification combining the severe and SCC groups
Benign

Mild

Moderate

Severe/SCC

Sensitivity (%)

75

67

39

66

Specificity (%)

49

38

86

75

Table 6-3 PLSDA classification combining the mild and moderate groups
Benign

Mild/Moderate

Severe

SCC

Sensitivity (%)

77

38

74

71

Specificity (%)

49

86

52

72
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(A)

(B)

(C)

(D)

(E)

Figure 6.4 ROC curves for (A) Benign (B) Mild (C) Moderate (D) Severe and (E) SCC
epithelial tisssues. The blue line is the estimated and the green the cross validated ROC curve.
AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the
crossvalidated AUC. The red dot(s) represents the calculated sensitivity and 1-specificty on the
y and x axis respectively. So for eaxample for (A) sensitivity is 0.74 (CV) and 1-specificity =
(1-0.49)=0.51.
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To better elucidate the variability between the different classes, their scores on the first latent
variable (LV-1) were plotted. This shows a large intra-class spread, the greatest spread being
observed in the moderate group and the smallest in the SCC (Figure 6.5).

Figure 6.5 A plot of the PLSDA scores according to LV-1

Plotting the means and standard deviations of the scores on LV-1 (Figure 6.6) does not show
an obvious progression, but it can be assumed from their means that the benign and mild are
mostly negative for LV-1 while moderate, severe and SCC are mostly positive.

124

Figure 6.6 Mean and standard deviation of PLSDA scores of LV-1

LV-1 (Figure 6.7), which is reponsible for 26.23% of the variance, has positive peaks at 783,
1371 and 1576 cm-1, which relate to nucleic acids (Table 5-3). Negative peaks are observed at
934, and 1282 cm-1 (relating to protein/collagen) and the amide 1 band at 1650 cm-1.
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Figure 6.7 LV-1 of the PLSDA model which included all the classes

Connective tissue

From their mean spectra, (Figure 6.8) the most notable difference between benign, mild,
moderate, severe and SCC connective tissue appears to be in the regions (800-1000 cm-1) and
(1200-1400 cm-1), similar to the findings of chapter 5 (Figure 5.5).
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Figure 6.8 Mean Raman spectra of benign, mild, moderate severely dysplastic and SCC
connective tissue. The spectra have been offset for clarity and shading denotes standard
deviation.

The results of the PLSDA classification (Table 6-4) show high sensitivities for benign and SCC
compared to the dysplasia classes. However, the specificity for benign was low, indicating a
high false positive rate. The classifier has the best accuracy among the classes for SCC
according to the ROC curve (Figure 6.9).
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Table 6-4 Sensitivity and specificity values obtained from PLSDA classification with
LOPOCV of connective tissue
Benign

Mild

Moderate

Severe

SCC

Sensitivity (%)

81

67

42

59

88

Specificity (%)

44

46

61

67

72

Plotting the scores of LV-1 shows the greatest intra-class spread in the mild group and the
smallest in the SCC (Figure 6.10). Plotting the means and standard deviations of the scores of
LV-1 (Figure 6.11) shows a progression from benign to SCC on LV-1. The means of the benign
and mild are negative in LV-1 while those of moderate, severe and SCC are positive.
Positive peaks of LV-1 can be observed at 1005, 1131, 1218, 1337, 1435 and 1581 cm-1 LV1(Figure 6.12). The peaks at 1005 and 1581 cm-1 relate to phenylalanine, while those at 1131,
1218 and 1435 cm-1 relate to lipids and that at 1337 cm-1 relates to nucleic acids. On the other
hand, negative peaks can be observed; at 811, 855, 938, 1241, 1453 and 1672 cm-1. The peaks
at (855, 938 and 1241 cm-1) relate to collagen while 1453 and 1672 relate to lipid contributions.
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(A)

(B)

(C)

(D)

(E)

Figure 6.9 ROC curves for (A) Benign (B) Mild (C) Moderate (D) Severe and (E) SCC
connective tisssues. The blue line is the estimated and the green is the cross validated ROC
curve. AUC is a measure of the accuracy of the classifier.
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Figure 6.10 A plot of the PLSDA scores of LV-1

Figure 6.11 Mean and standard deviation of PLSDA scores of LV-1
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Figure 6.12 Loading of LV-1 of the PLSDA model which included all the classes

6.4

Discussion

The use of benign lesions as a control category was for logistical reasons (as it is difficult to
get archival FFPP samples of patients with normal pathology). Besides, since clinicians do not
usually biopsy normal looking mucosa, it is important to differentiate dysplasia or cancer from
benign lesions. It was elected not to use the normal areas of dysplastic or SCC tissues because
previous studies have shown that the cells at the periphery of a malignant lesion may be subject
to cancer field effects, meaning that they appear histologically normal but have undergone
molecular changes8,9. LOOCV can tend to overfit the model and overestimate the accuracy of

131

the classifier. Hence LOPOCV, which is better at evaluating classifier performance on new
samples, was used.
Results from the PLSDA show a similar trend to the results of chapter 5, indicating increasing
nucleic acid contributions and lower protein and lipid contributions as dysplasia progresses in
the epithelium. According to the ROC curves, the accuracy of the classifier was highest for the
SCC class (AUC=0.71), intermediate (~0.6 AUC) for the benign, moderate and severe classes,
and lowest (AUC=0.46) for the mild. This is likely due to the fact that the mild is not a very
well defined category for the classifier leading it to misclassify with benign and moderate.
Moreover, the fact that combining the mild and moderate categories improves the classification
in the other categories reinforces that fact that there is considerable overlap between these
categories. The moderate group had the lowest sensitivity in the PLSDA classification and the
greatest spread in LV-1, suggesting a higher variability in this group compared to the others.
In connective tissue, nucleic acid peaks were more prominent with progressive dysplasia and
collagen peaks were less prominent. Connective tissue associated with SCC could be classified
from that associated with dysplasia and benign with a high sensitivity and specificity. This is
to be expected as, due to epithelial mesenchymal transition10; the boundary between epithelium
and connective tissue in SCC is often lost as a result of islands of epithelium invading the
connective tissue11.
When building a machine learning system or classifier, it is expected to be better than or match
the current state of the art, which in this case is histopathological diagnosis. The findings of
this study do not fulfil this standard which may be due to a number of factors. Firstly, the small
sample size makes it harder to build a representative model12, especially when the differences
between categories is small, as in this case with different degrees of dysplasia. Secondly, this
model is based on histopathological diagnosis but, as discussed in sections 1.3.5 and 5.1 ;
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morphological changes are not necessarily predictive of malignant transformation13. In fact, it
is now emerging that genetic alterations such as abnormalities in the number of chromosomes
(aneuploidy), losses at 3p, 9p and 17p and mutations in the P-53 gene can be a more important
prognostic marker14,15. Finally, factors other than the degree of dysplasia can have an influence
on the Raman spectrum and hence classification. These factors are investigated in chapter 7.
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Chapter 7:

Influence of patient factors and clinical features on

Raman classification
7.1

Introduction

Following on from the work of chapter 6, patient factors and clinical features that may have an
influence on the classification using Raman spectroscopy are explored. Tobacco smoke
contains carcinogens and has a well-studied connection with the development of both
dysplastic1 and malignant2 oral lesions, as has been discussed in detail in section 1.2.3.1 .
Similarly, alcohol consumption has been associated with the development of both oral
dysplasia1 and cancer2, as detailed in section 1.2.3.2 . The incidence of oral cancer is higher in
males than females3,4, which is likely due to habits such as smoking and alcohol consumption
rather than a genetic predisposition, although the prognosis is the same5. Gender was not found
to have an association with the development of oral dysplastic lesions1. Further variability can
arise because of the different sites of anatomical origin of the lesion. Oral cancer refers to any
cancer in the oral cavity proper which includes; the tongue, labial and buccal mucosa, hard and
soft palate, gingiva, alveolar ridges and floor of the mouth. These areas vary in degree of
keratinization, vascularity and lymphatic drainage5 and thus anatomic site may also influence
the spectroscopic signatures upon which a classification is to be based. As the interpatient study
was based on a heterogeneous group of patients with different gender, age, habits, medical
histories and lesion clinical features, the aim of this chapter was to discern whether these factors
have an influence on the classification using Raman spectroscopy.
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7.2

Methodology

7.2.1

Sample Preparation

The archival FFPP tissue samples detailed in section 6.2.1 were used in this study.
7.2.2

Instrumentation

Instrument and mapping properties were described in section 4.3.2 . The maps taken for section
6.2.2 were used in this study.
7.2.3

Data analysis

Metadata on the patients included in chapter 6 is provided in Table 7-1. This was used to divide
all the patients, regardless of histopathological diagnosis, into groups according to gender,
smoking habits, alcohol consumption and site of lesion. The spectral maps, acquired for the
study of chapter 6, were analysed using PLSDA with LOPOCV, as described in section 6.2.3
Table 7-1 Information on patient factors and clinical features
Patient Gender Age
1
2
3
4
5
6
7
8
9

M
F
M
F
M
F
F
F
F

59
38
86
75
50
66
45
32
59

10

F

61

11
12
13
14

F
M
F
M

62
71
62
21

Smoking

Alcohol
Consumption
No
Yes
n/a
n/a
No
Yes
No
Yes/rarely
n/a
n/a
No
Yes
N/A
n/a
Ex-smoker
No
No
Yes/2-3
units/fortnight
Yes
8-10 No
cpd/week
15-20 cpd
No
Ex-smoker
n/a
No
Yes/occasionally
n/a
n/a
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Site of Lesion
Retromolar area
Tongue
Tongue
Buccal mucosa
Tongue
Hard palate
Premolar ridge
Tongue
Buccal mucosa
Hard palate
Soft palate
Gingiva
Labial mucosa
Tongue

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

F
F
M
M
M
F
M
M
M
M
F
F
F
F
F
M
M
M
M
M
F
F
M
F
F
F
F
M
F
F
F
M
M
F
F
F
M
F
M
M
F
F

62
69
67
37
57
65
60
81
69
55
77
47
63
55
44
74
68
66
58
56
53
53
38
63
71
61
66
54
51
41
73
30
61
71
64
47
76
53
31
50
56

Ex-smoker
Yes 10 cpd
Ex-smoker
Yes
1-2 cpw
n/a
Ex-smoker
Ex-smoker
30 cpd
No
No
15 cpd
Ex-smoker
n/a
No
n/a
Ex-smoker
n/a
15 cpd
20 cpd
n/a
15 cpd
Ex-smoker
No
No
No
Ex-smoker
Yes 30 cpd
Ex-smoker
n/a
n/a
n/a
Yes 1 cpd
Ex-smoker
No
Ex-smoker
Yes
Ex-smoker
Ex-smoker
Yes
Ex-smoker
Ex-smoker

No
Yes
Yes
No
10 units/week
1-2 units/week
n/a
2-3 units/week
4 units/day
n/a
6 units/week
10-12 units/week
2 units/week
n/a
5-6 units/week
n/a
5 units/week
n/a
15 units/week
5-6 units/week
n/a
Yes 3 units/week
Yes
n/a
No
Yes
Yes
No
Yes
Yes 1 unit/week
Yes
n/a
Yes 20-30 units/week
Yes
No
Yes
Yes
Yes
Yes
No
No
No

n/a, information was not available
cpd, cigarettes per day
cpw, cigarettes per week
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Floor of the mouth
Tuberosity
Tongue
Buccal mucosa
Soft palate
Buccal mucosa
Hard palate
Tongue
Floor of the mouth
Maxilla
Gingiva
Tongue
Tongue
Labial mucosa
Tongue
Tongue
Soft palate
Labial mucosa
Buccal mucosa
Buccal mucosa
Floor of the mouth
Buccal mucosa
Tongue
Tongue
Labial mucosa
Soft palate
Alveolus
Buccal mucosa
Buccal mucosa
Tongue
Tongue
Tongue
Tongue
Buccal mucosa
Tongue
Buccal mucosa
Alveolus
Labial mucosa
Tongue
Tongue
Tongue

7.3

7.3.1

Results

Gender

The data of all the patients (Table 7-1) was split according to gender into females and males.
PLSDA results, expressed in terms of ROC curves, of epithelium (AUC =0.43) and connective
tissue (AUC=0.47) (figure 7.1) show no discrimination based on gender. The female vs male
sensitivity and specificity values were 22% and 77% respectively in epithelium. In connective
tissue the sensitivity was 62% and specificity was 44%.

(A)

(B)

Figure 7.1 ROC curves for (A) Epithelium and (B) Connective tissue of Female vs Male. The
blue line is the estimated and the green the cross validated ROC curve. AUC is a measure of
the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated AUC.
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7.3.2

Smoking

According to smoking status, the patients in table 7-1 were divided into 3 groups; non-smoker,
ex-smokers (previous smokers) and smokers.

Table 7-2 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in
epithelium
Non smoker

Ex-smoker

Smoker

Sensitivity (%)

83

81

52

Specificity (%)

46

38

88

The PLSDA results showed high classification sensitivity for Non-smokers and Ex-smokers
but lower specificities. On the other hand, the classification sensitivity was lower for smokers
but the specificity was higher (Table 7-2). The ROC curve (Figure 7.2) shows a significant
accuracy (AUC=0.76) of the classifier for smokers. To further understand the source of the
variance, non-smoker and ex-smokers were combined and the scores of LV-1 and LV-2 were
plotted against smokers (Figure 7.3). While there is some overlap, smokers are mainly negative
in LV-1 while non-smoker/ex-smokers are mainly positive. According to LV-1, negative bands
at 667, 784, 1372, and 1573 cm-1 suggest higher nucleic acids in the epithelium of smokers.
Non-smoker/ex-smokers had a more prominent amide I band at 1651 cm-1 and protein band at
934 cm-1 (Figure 7.4).
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(A)

(B)

(C)

Figure 7.2 ROC curves for (A) Non-smoker (B) Ex-smokers and (C) Smokers epithelium. The
blue line is the estimated and the green the cross validated ROC curve. AUC is a measure of
the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated AUC.
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Figure 7.3 Scores of Smokers and Non-smoker/Ex-smokers on the latent variables from the
PLSDA model.

Figure 7.4 Loading of LV-1 from PLSDA of Smokers vs Non-smoker and Ex-smokers in
epithelial tissue.
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In connective tissue, while there is some degree of classification (
Table 7-3), according to the ROC curves for non-smoker (AUC=0.43) ex-smokers (AUC=0.51)
and smokers (AUC=0.64), the accuracy is not significant (Figure 7.2).

Table 7-3 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in
connective tissue
Non smoker

Ex-smoker

Smoker

Sensitivity (%)

70

39

54

Specificity (%)

39

69

71
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(A)

(B)

(C)

Figure 7.5 ROC curves for connective tissue of (A) Non-smoker (B) Ex-smokers and (C)
Smokers. The blue line is the estimated and the green the cross validated ROC curve. AUC is
a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the crossvalidated
AUC.

7.3.3

Alcohol

Alcohol consumption in the patient group was varied (Table 7-1). For the sake of simplicity,
as the patient numbers were not large, they were divided into 2 main groups; alcohol consuming
and non-alcohol consuming. According to this grouping, PLSDA was performed on epithelium
(AUC=0.57) and connective tissue (AUC=0.63). No significant discrimination was found in
either based on alcohol consumption (Figure 7.6).
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(A)

(B)

Figure 7.6 ROC curves for (A) Epithelium and (B) Connective tissue of Alcohol consuming vs
Non-alcohol consuming. The blue line is the estimated and the green the cross validated ROC
curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the
crossvalidated AUC.
7.3.4

Anatomical Site of lesion

The lesions come from different anatomical sites in the oral cavity, as detailed in Table 7-1.
Raman spectra of lesions from the tongue, buccal mucosa, soft palate, hard palate and labial
mucosa were assessed using PLSDA with LOPOCV.
Table 7-4 Sensitivity and specificity values from PLSDA with LOPOCV for oral site in
epithelium
Tongue

Soft palate

Buccal

Hard palate Labial
mucosa

mucosa
Sensitivity (%)

81

50

32

40

72

Specificity (%)

31

83

72

41

27

While the sensitivity values for tongue and labial mucosa were high, 81 and 72% respectively,
(Table 7-4), the ROC curves (Figure 7.7) were not significant for any of the oral sites (all AUC
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values were less than 0.7). Similarly, in connective tissue the hard palate and the labial and
buccal mucosa could be classified with a high sensitivity (Table 7-5) but again AUC values
were not significant (Figure 7.8). Note that, in Figure 7.7(C) (D) and (E), there is a large
difference between the cross validated and estimated ROCs. This is likely due to the small
number of patients with lesions in these sites hence when one patients spectra are taken out this
is equivalent to a quarter of the dataset of that site which results in an unstable model6.

Table 7-5 Sensitivity and specificity values from PLSDA with LOPOCV for oral site in
connective tissue
Tongue

Soft palate

Buccal

Hard palate Labial
mucosa

mucosa
Sensitivity (%)

47

75

51

83

87

Specificity (%)

78

27

25

54

56

Grouping according to keratinised (Tongue and hard palate) and non ketatinised (soft palate,
buccal and labial mucosa) did not show a good discrimination, sensitivity of 33% and
specificity of 88% in epithelium and 35 and 75% sensitivity and specificity in connective tissue
respectively.
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(A)

(B)

(C)

(D)

(E)

Figure 7.7 ROC curves for (A) Tongue (B) Buccal mucosa (C) Soft palate (D) Hard palate and
(E) Labial mucosa of epithelial tissue. The blue line is the estimated and the green is the cross
validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated
and (CV) is the crossvalidated AUC.
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(A)

(B)

(C)

(D)

(E)

Figure 7.8 ROC curves for (A) Tongue (B) Buccal mucosa (C) Soft palate (D) Hard palate and
(E) Labial mucosa of connective tissue. The blue line is the estimated and the green is the cross
validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated
and (CV) is the crossvalidated AUC.
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7.3.5

Presence of inflammation

All the pathologies were evaluated for the presence of inflammation (H&E stained slides were
evaluated under a bright-field microscope by the investigator). Table 7-6 shows the number of
inflamed samples per class. PLSDA was used to classify inflamed vs non-inflamed for all the
pathologies combined. The results show that inflamed tissue can be classified from noninflamed tissue with sensitivity and specificity values of 68% and 70%, respectively, in
epithelium and 77% and 86%, respectively, in connective tissue. The AUCs were significant,
at 0.72 for epithelium and 0.84 for connective tissue (Figure 7.9).

Table 7-6 Number of inflamed samples per class
Class

Benign
(n=17)

Mild
(n=20)

Moderate
(n=20)

Severe
(n=10)

SCC
(n=5)

Number
Inflamed

2

3

9

7

5
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(A)

(B)

Figure 7.9 ROC curves for (A) Epithelium and (B) Connective tissue of Inflamed vs Noninflamed in all classes. The blue line is the estimated and the green the cross validated ROC
curve. AUC is a measure of the accuracy of the classifier, (C) is the calibrated and (CV) is the
crossvalidated AUC.
To ensure that the results obtained are due to the presence of inflammation rather than the
pathology (as most of the severe and SCC samples were inflamed which could skew the
results), inflamed vs non-inflamed was assessed in the moderate category. The results show a
very high accuracy in connective tissue (AUC=0.94) and, to a lesser extent, in epithelium
(AUC=0.69) (Figure 7.10). Plotting the scores of the latent variables shows a good separation
based on LV-1, the majority of inflamed spectra having negative scores while the majority of
non-inflamed spectra have positive scores on LV-1 (Figure 7.11). Note, the group of noninflamed that are outside the 95% confidence interval are likely from one patient who was
misclassified due to increased variability from the rest of the non-inflamed group. The loading
of LV-1 (Figure 7.12) shows positive peaks at 813, 855, 939, 1031, and 1245 cm-1 which relate
to collagen (Table 5-3), while the negative peaks relate to nucleic (1334, 1580 cm-1) and fatty
acids (1132, 1438 cm-1).
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(A)

(B)

Figure 7.10 ROC curves for (A) epithelium and (B) connective tissue of inflamed vs noninflamed in the moderately dysplastic lesions. The blue line is the estimated and the green the
cross validated ROC curve. AUC is a measure of the accuracy of the classifier, (C) is the
calibrated and (CV) is the crossvalidated AUC.

Figure 7.11 Scores obtained from the PLSDA model of inflamed and non-inflamed moderately
dysplastic connective tissue on the latent variables.
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Figure 7.12 Loading of LV-1 from the PLSDA model of inflamed vs non-inflamed connective
tissue

7.4

Discussion

The findings of the current study suggest that no clear Raman classification could be made
based on gender, alcohol consumption or site of lesion. The link between alcohol consumption
and carcinogenesis is not well understood, for, while alcohol can act as a synergistic agent for
other carcinogens, its main metabolite, acetaldehyde, is believed to have a role in DNA
damage9. Previous studies suggest that the risk of developing oral cancer increases with
quantity of alcohol intake10. Unfortunately this study was limited in that information on alcohol
intake quantities was not available for all patients. To date, no studies have looked at the effect
of alcohol on the oral mucosa using Raman spectroscopy. Previous studies have investigated
Raman classification of oral mucosal sites. Bergholt et al. found that the sites in normal/healthy
oral mucosa can be clustered into three groups; (1) buccal, inner lip, and soft palate; (2) dorsal,
ventral tongue, and floor; (3) gingiva and hard palate7. Sahu et al., studying normal, and
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malignant oral mucosa found that while the tongue and buccal mucosa could be classified by
Raman spectroscopy in healthy mucosa with some degree of accuracy, classification could not
be achieved in malignancy8.
From the results, it is apparent that some factors other than the degree of dysplasia can influence
the Raman classification. Smoking status was seen to impact on the classification of epithelial
tissue (AUC=0.76). This is consistent with previous work by Singh et al., who have shown that
the oral buccal mucosa of smokers is more likely to misclassify with that of premalignant
lesions than that of non-smokers11,12. This is likely due to the fact that smoking is an
aetiological factor in developing oral dysplasia, and hence biochemical changes occurring in
the mucosa of smokers are similar to those occurring in dysplastic lesions.
What was found to have a significant influence on the Raman classification, however, was the
presence of inflammation in connective tissue (AUC=0.94). Reduced collagen features and
increased nucleic acid features in the Raman spectra of inflamed connective tissue were the
main findings. The nucleic acid features may be due to increased cellularity caused by the
inflammatory cells infiltrating the tissue. The reduction of collagen features is likely due to the
breakdown of collagen by matrix metalloproteinases (especially MMP-8) which are
upregulated in inflammation13. In this study, most of the severely dysplastic and SCC tissue
was found to be inflamed, which is consistent with a previous study that has shown increasing
inflammatory cell infiltration with increasing severity of oral dysplasia and SCC14. The
presence of inflammation in the tumour microenvironment has been well documented15,16 and
is due to multiple factors. The environmental factors that prompt carcinogenesis, such as
alcohol and smoking, have been shown to trigger an inflammatory response17. Furthermore,
the tumour cells release inflammatory mediators which generate an inflammatory
microenvironment that promotes cancer growth, invasion and metastasis18. A study looking at
OSCC surgical margins found that inflamed connective tissue was more likely to misclassify
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with SCC than non-inflamed connective tissue19. Of note is the fact that the FFPP tissue from
chapter 5 (Figure 5.5) also showed inflammation which would explain the similar signature in
connective tissue.
While it has been reported that age related physiological changes can be discriminated with
Raman spectroscopy11, most of the patients in this cohort were between 50-60 years, and hence
there was not enough variation to study age related factors. Other patient factors and clinical
features which have not been considered, due to lack of metadata, can still have an influence
on the Raman classification. These include HPV and candida status of the patients, the size of
the lesions, and the degree of differentiation in the SCC lesions.
To sum up, these findings suggest that it is important when studying tissue pathologies to
consider them in the context of patient factors and clinical features which emphasises the need
for large scale studies with more representative patient samples.
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Chapter 8:
8.1
8.1.1

Conclusions and future work

Conclusions
Summary of findings

The primary objective of this thesis was to evaluate the potential of Raman spectroscopy in
diagnosing premalignant oral lesions. The first two chapters act as an introduction to the thesis,
Chapter 1:introducing clinical aspects of OSCC and dysplasia, while Chapter 2: places the
emphasis on diagnostic techniques. In Chapter 3: the aim was to establish whether Raman
spectroscopy can differentiate the different phases of the cell cycle in an oral squamous cell
carcinoma cell line and how that correlates with biomarker expression levels. The findings
were that Raman spectroscopy could differentiate the different phases of the cell cycle based
on nucleic acid, protein and lipid content. However it was not possible to correlate the
expression levels of cyclin D1 and PCNA to the Raman profiles. This may be due to the fact
that a Raman profile of a cell carries a great deal of information and, as many molecular
processes take place inside the cell, it is difficult to extract information on one particular
biomarker. This demonstrates both the strengths and weaknesses of Raman spectroscopy for
biological samples as it is sensitive in that it can detect small changes in the cell as it moves
through the cell cycle, but because it is a label free technique, distinguishing information on
one variable is more difficult. In Chapter 4:the aim was to optimise the FFPP tissue processing
for Raman spectroscopy. One of the main difficulties in performing Raman spectroscopy on
FFPP tissues is that the paraffin wax, in which the tissues are embedded, has a very intense
Raman signal and is hard to remove with the routine chemical dewaxing techniques which
change the composition of the tissue. The same is true of glass, which is generally used in
histopathology laboratories as a substrate for FFPP tissues .To solve the issues with the glass
and wax background; a novel method was developed whereby cell components were used as
inputs for NNLS subtraction and glass and wax matrices were digitally subtracted from the
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spectra. The use of matrices captures the variability in the wax or substrate spectra which
improves the subtraction. In Chapter 5:, the different levels of dysplasia; mild, moderate and
severe were assessed in the FFPP tissue sections within the same patients. This was done in
order to gain insight into the differences between the different levels of dysplasia without
influence from other patient variables. Using PCA-LDA with LOOCV, it was found that
Raman spectroscopy could classify the different levels of dysplasia with an accuracy of over
90% in epithelium and over 76% in connective tissue. In Chapter 6: benign, mild, moderate,
and severely dysplastic and SCC FFPP tissues were assessed in a cohort of patients using
Raman spectroscopy. PLSDA with LOPOCV was used for classification. The results showed
that SCC could be classified from the other pathologies with over 70% accuracy in epithelium
and connective tissue. However, the accuracy of Raman spectroscopy for differentiating
between different levels of dysplasia was lower. In Chapter 7: other variables which could have
an influence on classification based on the Raman spectra were assessed. From the results, it
was clear that smoking had the greatest influence in epithelium while the presence of
inflammation had the greatest influence in connective tissue.
8.1.2

Clinical relevance

Currently, there is a lot of interest in using Raman spectroscopy as a diagnostic aid. However,
a number of factors need to be evaluated before it can be translated into clinical use. For exvivo studies, using inexpensive substrates is of paramount importance. The novel method
developed in Chapter 4: for removing the substrate background has been used for a number of
varied studies1-4. The method is both reproducible and adaptable, as the pure components can
be selected based on the constituents of the cells/tissues/fluid under study. Furthermore, the
method of validation of the classifier is very important in determining how well it can classify
future (unseen) samples. For the interpatient studies, chapters 6 and 7, it was elected to use
LOPOCV as, although it has been shown to give lower accuracies than LOOCV5, due to the
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presence of biochemical differences between patients, it is better at evaluating classifier
performance on new samples as it avoids overtraining the model. While this study used ex-vivo
samples, the results can guide the development of the technique for in-vivo use. Having a
diagnostic aid such as Raman spectroscopy that can be developed for use chairside, would not
only aid in selecting the region to biopsy in large lesions, but can also reduce the number of
biopsies needed for monitoring. Important factors to consider in clinical translation include
instrument properties. The Raman instrument should be; small, easily transportable,
inexpensive, easily aligned and calibrated, and have an optical probe that is sterilisable6. The
finding that Raman spectroscopy can differentiate between cancer and dysplasia is very
important, as the management and prognosis is different for both. Dysplasia is a common
finding in tumour borders and regenerative changes which mimic dysplasia can often be found
in the margins of resected tumours7. The balance between being conservative and maintaining
as much of the tissue as possible, which is important both aesthetically and functionally, and
removing enough of the tumour to prohibit recurrence is a difficult one in oral cancer surgery.
Hence the ability of Raman spectroscopy to discriminate between cancerous and dysplastic
and/or healthy tissue can be important in striking that balance8.

8.2

Future perspectives

A more comprehensive study with a larger sample size9 which takes into account inherent
patient variability in addition to other variables such as age, smoking, alcohol consumption,
site of lesion, presence of inflammation etc. may result in a better classifier. The use of a larger
sample size would also allow for an independent validation set which can better evaluate the
performance of the classifier. The dataset in the current study did not include any dysplastic
lesions that had transformed into OSCC. However, a study looking at such lesions and
comparing them with dysplastic lesions that did not progress to OSCC in a given time period,
for example in a 5 year period, can be more informative, as morphology is not a predictor of
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malignant transformation. Hence, a study of transformed lesions could be of more value. As
Raman spectroscopy identifies molecular bonds that are common to many different
biomolecules as opposed to identifying individual biomolecules, changes with dysplasia/cancer
are often subtle and spectrally distributed, requiring full spectral scanning10. However, if
biomolecules are identified that both have an enhanced Raman signal and vary with increasing
dysplasia they can act as label free spectral markers which could make the Raman classification
faster and more accurate. Additionally, the Raman spectrum can be open to different
interpretations as to the source of the peaks. Although previous studies have explored the
biochemistry behind the various peak assignments there is still no accepted standardised
database for Raman peak assignments. Finally, it is difficult to compare Raman spectroscopic
studies of the oral mucosa as the sample collection, spectral processing and data analysis
techniques differ between laboratories, an international standardisation of protocols would go
a long way to taking Raman spectroscopy closer to clinical translation.
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Appendices

Appendix 1 Cell protocols
Cell Passaging
Cells were cultured in sterile vented culture flasks of size (25, 75 or 125cm2) depending on the
experiment. For passaging;
1. 3 ml of trypsin/EDTA solution are added to the flask to detach the adherent cells and
incubated for 3-5 minutes.
2. Once the cells have detached 7 ml of media are added to stop the trypsin and the cell
suspension is then transferred onto a sterile universal tube and centrifuged for 5 minutes
at 1200 rpm.
3. After centrifugation the supernatant is discarded carefully without disturbing the cell
pellet.
4. For a 1:10 split 10 ml of media is added to the cells which are then carefully
resuspended in the media.
5. In a new sterile cell culture flask 20 ml of media is added together with 1 ml of the cell
suspension from step 4.

Cell Counting
A Z series Coulter counter (Beckman Coulter Life Sciences) was used for cell counting. To
count the cells;
1. Cells are trypsinised and media added as in steps 1-2 of passaging.
2. 1 ml of the cell suspension is added to 20 ml of Isoton electrolyte solution in a vial
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3. Following set-up the vial is placed on the stage of the coulter counter and the stage is
moved up to the probe
4. To do the cell count press set up then start
5. A reading is displayed showing the number of cells/ml
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Appendix 2
Dewaxing protocol
1. Place slides in 1st xylene for 5 minutes
2. Transfer slides to 2nd xylene and leave for 4 minutes
3. Transfer slides to 1st ethanol and leave for 3 minutes
4. Transfer slides to 2nd ethanol and leave for 2 minutes
5. Transfer slides to IMS and leave for 1 minute
6. Transfer to water for 1 minute
H&E protocol
After step 6 of dewaxing;
1. Add a few drops of haematoxilyn to the tissue section (enough to cover the tissue) and
leave for 3 minutes
2. Rinse in running tap water for 5 minutes
3. Add a few drops of eosin and leave for 3 minutes
4. Rinse in tap running tap water for 2 minutes
Rehydrate and clear by passing through;
5. IMS for 3 minutes
6. Transfer to 1st ethanol for 3 minutes
7. Transfer to 2nd ethanol for 3 minutes
8. Transfer to 1st xylene for 3 minutes
9. Transfer to 2nd xylene for 3 minutes
10. Add a few drops of dpx mountant to the cover slip
11. Carefully place the slide over the cover slip
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